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AE    Adverse Event 
aEEG   Amplitude-integrated ElectroEncephaloGram 
bpm    Beats Per Minute 
CISMAC   Centre for Intervention Science in Maternal and Child Health 
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IQR    InterQuartile Range 
LMA    Laryngeal Mask Airway 
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PPV    Positive Pressure Ventilation 
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SAE    Serious Adverse Event 
SDG    Sustainable Development Goal 
SDG 3.2  Sustainable Development Goal number 3.2 
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Definitions       
Acidosis increased acidity in the blood and other bodily tissues  
Apgar backronym for Appearance, Pulse, Grimace, Activity and 
Respiration 
Apnoea episodes when a neonate fails to make an effort to respire 
Birth asphyxia combination of the lack of oxygen and tissue-ischemia in the 
foetus or neonate caused by disruption of placental blood-
flow, bleedings, uterine rupture, umbilical cord compression, 
infection or from a neonate failing to establish and maintain 
regular breathing at birth 
Cardiotocography parallel recording of the heart rate of the foetus in the uterus 
and uterine contractions  
Early Neonatal Death death within the first 7 days of life (WHO definition) 
Early Neonatal 
Mortality Rate 




procedure involving intubation of the trachea 
Electrocardiography recording of the electrical activity of the heart 
Extrauterine outside the uterus 
Foetus/foetal the unborn offspring of an animal/human 
Functional residual 
capacity  
the volume of air present in the lungs at the end of passive 
expiration  
Fresh stillbirths intrauterine death of a foetus during labour or delivery  
Gasping the last respiratory pattern preceding terminal apnoea (also 
referred to as agonal breathing)  
Gestational age a measure of the age of the pregnancy in weeks taken from 
the first day of the last menstrual period 
Grunting sound during expiration created by the neonate breathing 
against a slightly closed glottis 
Hypercapnia a condition of abnormally elevated carbon dioxide (CO2) 
levels in the blood 
Hypoxia (cerebral) oxygen deprivation (to the brain) 
Innovation  creation, development and implementation of a new product, 
process or service, with the aim of improving efficiency, 
effectiveness or competitive advantage 
Intrapartum  period from the onset of labour to birth 
Intrauterine inside the uterus 
Ischemia restriction in blood supply to tissue, causing a shortage of 
oxygen needed for cellular metabolism 
Macerated stillbirths intrauterine death of a foetus where it has started to 
decompose 
  




mHealth medical and public health practice, supported by mobile 
devices, such as mobile phones, patient monitoring devices, 




neonatal death during the first 28 days of life per 1000 live 
births (WHO definition) 
Perinatal Mortality 
Rate 
number of stillbirths and neonatal deaths from 28 completed 
weeks of gestation until the first 7 days of life per 1000 
births (WHO definition) 
Peak Inspiratory 
Pressure  
the highest level of inflation pressure applied to the lungs 
during inspiration 
Primary apnoea asphyxiated neonates’ initial response during positive 
pressure ventilation with an increased respiratory rate 
followed by apnoea, a drop in heart rate and increase in 
blood pressure. During this phase, most neonates will 
respond to stimulation and ventilation, with return of 
spontaneous respiration 
Postpartum period beginning immediately after birth 
Positive pressure 
ventilation 
delivery of air into the lungs by positive pressure 
Respiratory function 
monitor  
a monitor collecting information, such as airway pressures, 
flow and tidal volumes 
Secondary apnoea occurs when asphyxia continues after primary apnoea; a 
neonate responds with a period of gasping respiration, a drop 
in heart rate, and a fall in blood pressure. The neonate takes a 
last breath and then enters the secondary apnoea period. The 
neonate will not respond to stimulation alone, and death will 
occur unless resuscitation begins immediately. Immediately 
after birth, it is impossible to differentiate between primary 
and secondary apnoea 
Stillbirth  a neonate dying at a late stage of pregnancy, before or during 
birth (WHO definition) 
Strategy an action aimed at achieving a desired goal in the future  
Tidal volume  inhaled and exhaled volume of air during a breath 
Very early neonatal 
death 
death within the first 24 h of life (WHO definition) 
 
  






Background: Lack of oxygen at birth, birth asphyxia, accounts annually for around 
700 000 deaths. Heart rate is important in evaluating a neonate and effective positive 
pressure ventilation (PPV) may prevent neonatal deaths. Evaluating heart rate by 
auscultation may be inaccurate and standard face-mask ventilation (FMV) may be 
inadequate. NeoTap Life Support (NeoTapLS) is a free-of-charge smartphone app for 
heart rate recording designed for low-resource settings. The laryngeal mask airway 
(LMA) is a tube used as an alternative to a face mask. Both of these innovations may 
be task-shifted to midwives who are on the front-line of neonatal resuscitation in low-
resource settings. This thesis reports on investigations into whether these innovations 
and new strategies can potentially increase adherence to guidelines and thereby 
reduce neonatal mortality and morbidity.  
Methods: Two observational studies and a clinical trial were conducted in Sweden 
and Uganda between 2014 and 2019. We investigated the accuracy and speed of heart 
rate assessment by NeoTapLS compared to a manikin, a metronome, pulse oximetry 
and electrocardiography, in simulations and in clinical use. A phase III open-label 
superiority randomized clinical trial, the NeoSupra Trial, compared LMA with face 
mask as a primary device for neonatal resuscitation carried out by midwives. The 
study involved neonates at ≥34 weeks of gestation and/or an expected birth weight of 
≥2000 gram, thereby requiring PPV at birth. The primary outcome was a composite 
of 7-day mortality and moderate-to-severe hypoxic-ischemic encephalopathy, daily 
evaluated by Thompson scoring through Day 5.  
Results: Simulation studies showed a high correlation between measured and true 
values. In the manikin study, 93.5% of the auscultations and 86.3% of the palpations 
differed by ≤5 beats, mean acquisition time 14.9 vs. 16.3 s. In the metronome study, 
77% differed by ≤10. In clinical assessment by doctors of neonates not needing PPV 
88% differed by ≤10 and by midwives in neonates needing PPV 48% differed by ≤10, 
median acquisition time 5 vs. 2.7 s. NeoTapLS showed very good sensitivity and 
specificity in detecting heart rate <100 bpm. The NeoSupra Trial had a complete 
follow-up data of 99.2%; the primary outcome occurred in 27.4% in the LMA arm 
and 24.4% in the FMV arm (adjusted relative risk, 1.16; 95% confidence interval 
0.90 to 1.51; P=0.26). Seven-day mortality was 21.7% in LMA and 18.4% in FMV 
(adjusted relative risk 1.21; 95% confidence interval, 0.90 to 1.63). The proportion of 
moderate-to-severe HIE was 11.2 vs. 10.1% (adjusted relative risk, 1.27; 95% 
confidence interval, 0.84 to 1.93). Intervention-related adverse events were few and 
similar between the arms. 
Conclusion: NeoTapLS is well adapted in the context it was used for swift and 
accurate heart rate recording by doctors. Clinical assessment by midwives was less 
accurate, suggesting that they may benefit from auscultation-focused training. LMA 
was safe in the hands of midwives but was not superior to a face mask in reducing 
early neonatal death and moderate-to-severe hypoxic-ischemic encephalopathy. It is 
suggested further investigations of these innovations and new strategies to explore the 
possibility of task-shifting its use to midwives in low-resource settings.   
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Thesis at a glance (article I-III) 
Article I  
Aim 
 
To determine the accuracy and speed of the NeoTap Life Support (NeoTapLS), a 





30 participants: eight doctors, six nurses, three nurse assistants, six nurse 
students, two medical students, three secretaries and two web designers. 
This observational manikin study was carried out at Sachs’ Children and Youth 
Hospital, Sweden. Participants used the NeoTapLS app to determine a randomly 
selected heart rate by auscultation and palpation using a Laerdal SimNewB 
manikin that simulates heart rates, defined as true values.  
Results 
 
1200 measurements were carried out. A high correlation was found between 
measured and true values by auscultation (Pearson´s correlation coefficient, 
0.993) as well as by palpation (Pearson´s correlation coefficient, 0.986) with 
93.5% of the auscultations and 86.3% of the palpations differing from the true 
value by five beats or fewer. The mean time to the first estimated heart rate was 
14.9 seconds for auscultation and 16.3 seconds for palpation. 
Conclusion Heart rates could be accurately and rapidly assessed using the NeoTapLS app on 
a manikin.  
Article II  
Aim 
 
To evaluate the NeoTapLS app, which records heart rate with a screen-tapping 





Phase one and three: 18 low-end users (midwives). Phase two: 2 high-end users 
(paediatric specialists). 
This observational study was carried out in Uganda in three phases. In phase one, 
a metronome rate (n=180) was recorded by low-end users using NeoTapLS. In 
phase two, heart rate (n=69) in neonates not needing positive pressure ventilation 
(PPV) was recorded by high-end users using NeoTapLS versus pulse oximetry. In 
phase three, heart rate (n=235) in neonates needing PPV was recorded by low-
end users using NeoTapLS versus electrocardiography (ECG). 
Results 
 
In high-end users, the mean difference was 3 beats per minute (bpm) higher with 
NeoTapLS versus pulse oximetry in neonates not needing PPV (95% agreement 
limits, −14 to 19 bpm), with median acquisition time of 5 seconds. In low-end 
users, the mean difference was 6 bpm lower with NeoTapLS versus metronome 
(95% agreement limits, −26 to 14 bpm) and 3 bpm higher with NeoTapLS versus 
ECG in neonates needing PPV (95% agreement limits, −48 to 53 bpm), with 
median acquisition time of 2.7 seconds. The agreement between NeoTapLS and 
ECG was good in heart rate categories of 60–99 bpm and ≥100 bpm (kappa index 
0.71, 95% confidence interval, 0.63 to 0.79). Heart rate <60 bpm had few 
measurements.  
Conclusion Heart rate could be accurately and rapidly assessed by high-end users using a 
smartphone application in neonates not needing PPV in a low-resource setting. 
Clinical assessment by low-end users in neonates needing PPV was less accurate 
with wider confidence interval but adds clinically important information.  











To investigate if ventilation with a cuffless laryngeal mask airway (LMA) over 
face mask has potential advantages on mortality and morbidity during neonatal 
resuscitation in asphyxiated neonates in a low-resource setting.  
1163 participants, neonates needing PPV with gestational age >34 and birth 
weight >2000 gram (566 LMA, 597 face mask) 
Methods 
 
This phase III open-label superiority randomized controlled clinical trial in 
Uganda compared the use of an LMA versus face mask in neonatal resuscitations 
performed by midwives. The primary outcome was a composite of 7-day 




The follow-up rate was 99.2%. The primary outcome occurred in 154/563 
(27.4%) neonates in LMA and 144/591 (24.4%) in face mask arms (adjusted 
relative risk, 1.16; 95% confidence interval, 0.90 to 1.51; P=0.26). Seven-day 
mortality was 21.7% in LMA and 18.4% in face mask arms (adjusted relative 
risk, 1.21; 95% confidence interval, 0.90 to 1.63). The proportion of moderate-to-
severe hypoxic-ischemic encephalopathy was 11.2% in LMA and 10.1% in face 
mask arms (adjusted relative risk, 1.27; 95% confidence interval, 0.84 to 1.93). 
Rates and main analysis were based on complete cases; findings were materially 
unchanged in the sensitivity analysis. The frequency of pre-defined intervention-
related adverse events was low and similar between the arms.  
Conclusion In asphyxiated neonates needing PPV, LMA was safe in the hands of midwives 
but was not superior to face mask in reducing early neonatal death and moderate-
to-severe hypoxic-ischemic encephalopathy. 
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This thesis discusses how best to support non-breathing neonates immediately after 
birth in low-resource settings using innovations and new strategies. The thesis will be 
focused on heart rate (HR) assessment using a smartphone app, and airway access for 
ventilatory support with the use of a laryngeal mask airway (LMA), following its 
effect on adherence to international neonatal resuscitation guidelines and effect on 
neonatal mortality and morbidity. To understand why some neonates need assistance 
at birth, I will first introduce the physiological transition occurring in neonates during 
a normal birth and what can go wrong. 
1.1 Happy Birthday 
In the majority of births, the neonate does not need advanced intervention to start 
breathing. There is a wide range of what is referred to as a ‘normal’ birth, and the 
experience is different both for mothers and neonates. A ‘normal’ birth could be 
described as a spontaneous start of labour between 37-42 weeks of pregnancy and the 
birth of a neonate breathing within the first 30 s of life.1,2 It could also include 
immediate skin-to-skin contact after delivery and breastfeeding within the first hour 
of birth. However, even in a ‘normal’ delivery the neonate undergoes a dramatic 
transition from intrauterine (within the uterus) to extrauterine (outside the uterus) life. 
1.2 Transition to extrauterine life 
The transition from intrauterine to extrauterine life for the foetus, is a chain of 
physiological events in both circulation and respiration that are not fully understood 
to this day. The transition is driven by a number of events.3-6 Before birth the foetus is 
supported by the placenta, for example for oxygenation (Figure 1a). After birth, the 
neonate is oxygenated by gas exchange in his/her own lungs (Figure 1b).  
The ductus arteriosus is a vascular foetal structure connecting the proximal 
descending aorta to the roof of the main pulmonary artery. In normal cases, the 
ductus arteriosus closes after birth and becomes the ligamentum arteriosum. This is 




due to a shift of blood-flow from the placenta to the pulmonary vessels, resulting in a 
left-to-right flow through the ductus arteriosus, which leads to ductal closure. 
 
Figure 1. a) Foetal and b) neonatal circulation. From Textbook of Neonatal 
Resuscitation, 7th ed., 2016. Adapted by Abbe Höök and published with the kind 
permission of the American Academy of Pediatrics. 
Foetal breathing movements starts in the 11th week of gestation. On the day of birth, 
pressure in the birth canal, changes in temperature and changes in circulation have 
been considered factors triggering the start of breathing. At birth the fluid-filled non-
inflated lungs with high resistance become filled with air during the first breath. The 
lungs should remain filled with air, creating a space for air even after exhalation, 
called the functional residual capacity. The mean oxygen saturation during 
intrauterine life is ~58%7 and may drop to as low as 30% during labour.8 Median 
peripheral capillary oxygen saturation after birth reaches 68% at 1 min, 92% at 5 min 
and 97% at 10 min in term neonates.9 Neonates normally clear their airways of fluid 
within 2-5 breaths, and the cardiac output from the right ventricle is shifted towards 
the lungs (Figure 1).10  
  





A study of rabbits showed that air/liquid only moved toward the distal airways during 
inspiration, indicating that pulmonary pressures plays an important role in airway 
liquid clearance at birth.11 Breathing efforts in healthy neonates and ventilation in 
non-breathing neonates affecting the HR have been investigated in recent years; they 
show that HR increase spontaneously in the first min after birth in breathing neonates 
with a minimal effect of cord clamping, and a consistent positive relationship 
between delivered volumes and HR increase from <100 beats per min (bpm) to a 
stable HR ~160 bpm after 2-3 min.12-14  
1.3 Birth asphyxia 
The need for interventions at birth are common, with ~10% of neonates requiring 
some assistance at birth.2,15,16 Many of these neonates start breathing after tactile 
stimulation, which refers to warming, drying the skin and rubbing the back or the 
soles of the feet of the neonates, measures recommended in the guidelines to 
stimulate breathing.17-20 How it acts is unclear, but experimental studies have 
validated a positive effect.21,22 However, a recent retrospective video-analysis of 
preterm neonates showed that only in a small proportion had an effect that could be 
observed on video.23  
Birth asphyxia is the lack of oxygen in combination with tissue-ischemia, which may 
cause brain injury and death. Birth asphyxia, nowadays, often referred to as 
intrapartum (i.e. during childbirth) related events, accounts for ~23% of neonatal 
mortality, leading to ~700 000 deaths/year.24-26 Asphyxia can occur prior to the birth 
due for instance to placental blood-flow disruption, bleeding, uterine rupture, 
umbilical cord compression and infection. At birth, asphyxia is caused by failure to 
establish and maintain regular breathing due to respiratory or cardiovascular 
impairment, such as insufficient breathing efforts, secretion plugs or cardiac 
abnormalities, leading to hypoxia, hypercapnia and respiratory or metabolic acidosis. 
But a combination of intrapartum and postpartum asphyxia is common.  
Hypoxia due to birth asphyxia should be differentiated from other causes of brain 
injury, such as congenital metabolic diseases.27 Intrapartum related events can be 
identified by monitoring abnormalities in foetal HR, thereby indicating a possible 




need for resuscitation efforts, and can be associated with fresh stillbirth (intrauterine 
death of a foetus during labour) and early neonatal deaths (death within the first 7 
days of life).28-30 Observation of postpartum events will be discussed later. 
In a high-resource setting, with a strong and well-equipped healthcare system, doctors 
and nurses on call 24/7 use advanced interventions to give every neonate a chance of 
survival. In low-resource settings, there is often a lack of health personnel, training, 
equipment and medicines, leading to inadequate or absence of the appropriate 
interventions.  
Hypoxic-ischemic encephalopathy (HIE) is brain injury caused by hypoxia-ischemia; 
it is a serious health problem that often leads to long-lasting neurological 
consequences, such as neurodevelopmental disabilities - seizure disorder, cerebral 
palsy and learning disability.31 An estimated 3‐5 per 1000 live term-births are 
affected.32 In low‐resource settings, the incidence may be 10-fold higher.33 Cooling 
criteria have been used as a criterion for initiating brain protection by therapeutic 
hypothermia treatment in high-resource settings.34 These are, for example, an Apgar 
score of 5 or less at 10 min, ongoing resuscitation at 10 min, metabolic or mixed 
acidosis within the first hour of life. Studies, including 3 systematic reviews, report 
that therapeutic hypothermia is a way to treat HIE, and have been shown to be 
effective in reducing death and disability. It is safe to use in intensive care in high‐
resource settings.35-39 Treatment should be started as soon as possible but within 
6 hours (h) after birth; the target core temperature is 33.5 ± 1°C, with the treatment 
lasting for ~72 h.40,41 
A systematic review and metanalyses on all published randomised or quasi-
randomised controlled trials of therapeutic hypothermia in low-and middle-income 
countries was published in 2013.42 They concluded that it was not associated with a 
statistically significant reduction in neonatal mortality, although the confidence 
intervals were wide and not compatible with results seen in high-income countries. 
They suggested part of this may be due to a sicker population and suboptimal care at 
the neonatal intensive care units (NICUs). There is a lack of adequately run clinical 
trials on cooling in low-resource settings.43 Existing methods of therapeutic 





hypothermia are expensive and difficult to translate into practise in low-resource 
settings due to, for example, the inability to cool during transport, and often the long 
distances to NICUs that have an adequate power supply and the right equipment. 
New inventions are under investigation.44 
1.4 Neonatal mortality  
Neonatal mortality, defined as deaths within 28 days of life, has decreased by 51% 
from 1990 to 2018, i.e. from ~5.0 to ~2.5 million, currently accounting for 47% of all 
under-5 deaths worldwide.45 This is, of course, a great success, but neonatal mortality 
varies widely globally, and most of sub-Saharan Africa, the Eastern Mediterranean 
and South Asia are lagging behind (Figure 2). Nevertheless, today ~1 million 
neonates die on the first day of life and further 2 million within 6 days.45 Stillbirths 
accounts for ~2.6 million deaths per year, half of which occur after the onset of 
labour.46 
It is clinically difficult to distinguish fresh stillbirths and intrauterine death of a foetus 
during labour or delivery from neonates suffering from severe birth asphyxia.46,47 
This probably influences the estimated global perinatal mortality rate. 
Figure 2. Neonatal mortality rate (deaths per 1000 live births) by country, 2018. 
Levels & Trends in Child Mortality Report 2019. Estimates developed by the UN Inter-
agency Group for Child Mortality Estimation  Note: The classification is based on 
unrounded numbers. Published with the kind permission of UNICEF. 




To reach the Sustainable Development Goal number 3 target 3.2 (SDG 3.2) in each 
country reporting a neonatal mortality rate of ≤12 per 1000 births by 2030,48 
improvement in neonatal resuscitation is crucial.49-51 About 60 countries have to 
accelerate their efforts to reach the target.24,52,53 Many efforts have been made, such 
as the global Every Newborn Action Plan launched in 2014, which provided a road- 
map of strategic actions for ending preventable neonatal mortality and stillbirth, 
thereby contributing to reducing maternal mortality and morbidity.54 The plan was 
based on evidence published in The Lancet Every Newborn series.26 In a constantly 
developing world, translation into practice of new evidence-based tools, innovations 
and new strategies must focus on reaching the most vulnerable people in the world, 
i.e. neonates in low-resource settings.55 
1.5 Neonatal resuscitation 
For neonates that are not breathing, state-of-the-art resuscitation is of utmost 
importance for a healthy survival.51 Most studies report that 3-6% of neonates do not 
respond to stimulation alone, which means that approximately 6 million neonates a 
year need resuscitation at birth.2,15,16 Advanced resuscitation (i.e. chest compressions, 
intubation, or medications) is required for <1% of all neonates.16 Positive pressure 
ventilation (PPV) is the delivery of air into the lungs. If PPV is not administrated or is 
ineffective, birth asphyxia may develop or be aggravated.56 Deprivation of oxygen 
affects the organs, such as the heart, reducing its beating with the result that less 
blood reaches the brain, potentially causing injury.  
A normal foetal HR is considered to be 120-160 bpm, based on expert consensus. 
Neonates needing PPV are considered to suffer from either primary or secondary 
apnoea, the two initially possibly looking alike. In primary apnoea, the neonate 
typically has a HR >60 bpm, and may respond to stimulation or ventilation relatively 
quickly by starting to breathe.57,58 A neonate in secondary apnoea typically has a HR 
<60 bpm, and stimulation is insufficient; the neonate may respond with occasional 
irregular breaths (gasping), decrease in HR and falling blood pressure if PPV is not 
immediately given (Figure 3).  
 






Figure 3. Physiological changes associated with primary and secondary apnoea 
in the neonate. Adapted by N. Pejovic from Kattwinkel Neonatal Resuscitation 
Textbook, 5th Edition, 2006, with the kind permission of N. Pejovic. 
1.5.1 The International Liaison Committee on Resuscitation (ILCOR)  
Neonatal resuscitation is an emergency intervention and all health personnel involved 
in the delivery or care of neonates should be prepared to provide immediate 
resuscitation of neonates needing PPV. All health personnel are called to follow 
internationally accepted guidelines for best practice. The International Liaison 
Committee on Resuscitation (ILCOR) was formed in 1992 in collaboration with 
major resuscitation organisations worldwide. ILCOR released its first treatment 
recommendations for neonatal resuscitation in 2000, based on the latest available 
evidence. It has since issued updated recommendations every fifth year, focusing on 
resuscitation practices in high-resource settings (Figure 4).17,18,20 The ILCOR 2015 
Consensus on Sciences with Treatment Recommendations (CoSTR) was considered 
when planning the studies for this thesis. How proper HR assessment should be 
performed and PPV should be given in low-resource settings, where training and 
adequate equipment may be lacking, has yet to be defined by ILCOR.  
 
 




Figure 4. The 2015 ILCOR action plan for neonatal resuscitation. Published with the 
kind permission of Elsevier. 





1.5.2 Helping Babies Breathe (HBB) 
International guidelines have historically focused on resuscitation in high-resource 
settings. Low-resource settings, where most of the neonatal deaths occur, have been 
lacking appropriate training material for health personnel and appropriate equipment 
suited in this context. The World Health Organization (WHO) took the lead in 
creating a basic neonatal resuscitation curriculum, publishing in 1998 the first 
guideline targeting low-resource settings.59 The American Academy of Pediatrics and 
partners followed, which developed Helping Babies Breathe (HBB), recently updated 
in a 2nd edition (Figure 5).60-62 HBB is based on the ILCOR guidelines with a focus on 
prompt PPV in non-breathing neonates. They have produced a set of instructions and 
tools for easy teaching and training: a color-coded action plan, flip charts, 
workbooks, a mannequin and other equipment.63,64 The concept of The Golden 
Minute© teaches first assessments and care of neonates and informs that PPV should 
start within 1 min after birth in neonates requiring it. After implementing HBB in 8 
hospitals in Tanzania in 2009, a 47% reduction in early neonatal death and a 24% 
reduction in fresh stillbirths were reported; HBB introduction in India reduced 
intrapartum stillbirth rate by 46%.65,66 However, another study in Tanzania reported a 
better performance in simulated neonatal care and resuscitation 7 months after one 
day of HBB training, but the improvement did not transfer to clinical practice.67 Since 
the rollout of the HBB program in 2010, workshops have taken place in >80 countries 
and a network of master trainers has been instructed.68 The HBB action plan does not 
teach advanced resuscitation (e.g., chest compressions), interventions that could be 
relevant to referral hospitals in low-resource settings.15 HBB is now included in 
Helping Babies Survive (HBS) evidence-based, hands-on training programs 
developed to reduce neonatal mortality in low-resource settings.69 HBS began with 
the HBB neonatal resuscitation techniques, but now also includes the programs 
‘Essential Care for Every Baby’, ‘Essential Care for Small Babies’ and ‘Improving 
Care of Mothers and Babies: A guide for improvement teams’. 
 





Figure 5. Helping Babies Breathe (HBB) action plan, 2nd edition. Published with the 
kind permission of the American Academy of Pediatrics. 





1.6 Assessment of neonates  
The assessment of neonates immediately after birth is the cornerstone of neonatal 
resuscitation, in which time is an extremely important factor. Primary assessment is 
both visual and physical. The colour, tonus and breathing efforts of the neonate are 
essential, as are the assessment of HR guiding resuscitation efforts.  
1.6.1 Apgar  
In high-resource settings, the analysis of cord blood may indicate the severity of birth 
asphyxia. In low-resource settings, blood tests are normally unavailable and health  
personnel will base their assessment of the severity of asphyxia on ventilation time 
and the Apgar score. This score was invented by Virginia Apgar in the 1950s as a 
method of clinically evaluating neonates, being used in both high- and low-resource 
settings.70-73 Five variables are scored 0-2 each: HR, breathing, skin colour, muscle 
tone and reflex irritability, giving a maximum score of 10. It is assessed at 1 and 5 
min, but at 10 min or more was added at a later stage, called the expanded Apgar 
score.72 Apgar gives an indication of the state of the neonate, but does not reveal the 
aetiology or prognosis.74 A low Apgar score (<7) at 5 min is associated with higher 
risk of HIE.75-77 
1.6.2 Heart rate (HR) 
HR is one of the most important clinical parameters used to evaluate a neonate, to 
guide the management and predict the outcome.19,78,79 HR reflects the state of the 
foetus or neonate both during and after birth and indicates whether the foetus/neonate 
is suffering hypoxia. The most common way for physicians to measure HR in a 
neonate is by auscultation. This is a 3-step procedure; first, auscultating the heart, 
second interpreting what is heard (first and second heart sounds), and third translating 
it by a number by an algorithm. The HR value of neonates is conventionally 
classified into 3 categories: <60 bpm very low; 60–99 bpm low and 100 bpm or 
above normal HR. Apnoea (no breaths), gasping (irregular breaths) and an HR <100 
bpm are the threshold indicators for starting PPV, and a HR <60 bpm despite 
effective ventilation is the threshold for starting chest compressions.  




Guidelines suggest HR assessment and start of PPV within 60 seconds (s) for 
neonates needing PPV.17,20 Evaluation of HR by auscultation and palpation has been 
proven to be imprecise, even when assessed by doctors in high-resource settings.80-84 
However, doctors HR assessment by auscultation compared to pulse oximetry and 
electrocardiography (ECG) has recently been shown to be quick and reasonably 
accurate in neonates not needing PPV.85 Studies during neonatal resuscitation with 
less experienced health personnel are lacking. Neither pulse oximetry nor ECG is fast 
enough to enable delivery room personnel to follow international resuscitation 
guidelines of HR within 60 s after birth, and HR by auscultation and palpation is 
inaccurate.86-90 Nevertheless, HR determination by physical examination is 
recommended if pulse oximetry and/or ECG are unavailable.17,19,91 ECG remains the 
gold standard to continuously monitor a neonate´s HR immediately after birth, 
meaning that, according to most reviews, this is the best available way to monitor 
HR.89,92 ECG is faster in giving the first HR value compared to pulse oximetry,93,94 
but both are relatively expensive and rarely available in low-resource settings. ECG 
can also be difficult to apply due to wet skin and hence it becomes time-consuming.95 
Pulse oximetry is sensitive to excessive motion and low blood perfusion, making it 
slow and often unreliable in the delivery room. One study reported a median of 68 s 
needed to obtain a HR.95 In an observational study, the mean time interval from 
attaching the pulse oximeter on the neonate to the first displayed HR was 84 s.96  
The HBB action plan (Figure 5) includes assessment of HR, and the training kit 
includes a plastic stethoscope. However, the training program does not include any 
specific auscultation-focused training; non-doctoral health personnel in low-resource 
settings rarely have sufficient training or access to a personal stethoscope.15 The 
assessments of HR by non-doctoral health personnel are prone to be incorrect and 
may lead to inadequate interventions and adverse outcomes.97  
  





1.6.3 Breathing/respiratory rate 
Assessing the breathing effort in the neonate is done by a visual check of chest-rise 
and by auscultation. The breathing should be regular with a rate of 30-60 per min. 
Grunting is an expiratory sound made by a neonate breathing against a slightly closed 
glottis. It is common as the neonate’s way of creating a pressure and keep air in the 
lungs, ensuring they do not collapse and remain open. Gasping are irregular breaths at 
~12 per min and may be misinterpreted as breathing.98 It can be a sign of hypoxia 
and/or decreased perfusion of the brain, as well as being a possible indicator of 
cardiac arrest. Neonates showing this behaviour should be promptly resuscitated.99 
Any irregular breathing must be further investigated. 
1.6.4 Assessment of hypoxic-ischemic encephalopathy (HIE) 
HIE is a leading cause of neonatal mortality and morbidity that affects at least one 
million neonates each year.100 Neonates can compensate for brief periods of oxygen 
depletion, but if the hypoxic event is too long, brain tissue will start to be damaged. 
Data from Uganda showed that asphyxiated neonates had signs of major recent brain 
injury using early cerebral ultrasound imaging, suggesting prolonged or severe acute 
exposure to hypoxia.101,102 Death and neurodevelopmental disability were common 
and early clinical parameters predicted impairment outcomes. The current 
understanding of longer-term childhood outcomes of asphyxia in low-resource 
settings remains limited. 
The Thompson score is a clinical tool to assess the severity of HIE of a neonate in the 
first days of life following birth asphyxia. The score has a high sensitivity and 
specificity predicting HIE and adverse outcomes (death or severe disability).103,104  
The Thompson score is based on daily assessments of 9 neurological parameters of 
neonates born with birth asphyxia (Table 1), with a maximum score of 22.  
In normothermic neonates, a maximum score of >10 any day during the first 7 days 
of life predicts an abnormal outcome with 100% sensitivity and 61% specificity.103  
A Thompson score of ≥7 predicts an abnormal 6-h amplitude-integrated 
electroencephalogram (aEEG; sensitivity 100%, specificity 67%) and is consistent 




with cooling criteria.105 A 2-year follow-up of HIE survivors with a Thompson score 
of 6-10 reported abnormal outcome in 20.6% of the patients.101 More recently a 
statistically significant correlation between mortality and morbidity and day 1 
Thompson score was reported.104 
The decision to use Thompson scoring in our trial was based on the fact that previous 
studies at the study site in Uganda had used this method.101,102,106 
Table 1. The Thompson score assessing 9 neurological parameters. The maximum 
score is 22. 
Sign 0 1 2 3 
Tone Normal Hyper Hypo Flaccid 
Level of consciousness Normal  Hyperalert/stare Lethargic Comatose 
Fits None  <3 per day >2 per day - 
Posture Normal  Fisting, cycling Strong distal flexion Decerebrate 
Moro Normal  Partial Absent - 
Grasp Normal  Poor Absent - 
Suck Normal  Poor Absent+ bites - 
Respiration Normal  Hyperventilation Brief apnoea Apnoea 
Fontanel Normal  Full, not tense Tense - 
 
  





2 Innovations and new strategies 
Innovation is the creation, development and implementation of a new product, 
process or service, with the aim of improving efficiency, effectiveness or competitive 
advantage. A strategy is an action aimed at achieving a desired goal in the future. A 
pubmed search in 2013 for medical devices addressing the health of neonates in low-
resource settings, reported few innovations or new strategies for neonates in peer-
reviewed medical journals.107 Most devices were infant warmers, neonatal 
resuscitators, and phototherapy devices. In 2015, the same group made a systematic 
review which showed that most neonatal health devices being reported were in fact 
iterations of already existing interventions, not innovations, and were only modified 
for a new context equal to new strategies.108 Rigorous randomized trials focusing on 
outcomes were rare. It was concluded that there was a need to assess the impact of 
innovations on health outcomes and provide evidence on the potential for scale-up, 
feasibility and acceptability. 
Making innovations and new strategies available to health personnel in low-resource 
settings at the time and place of birth is essential. There is not only a need for new 
devices and strategies, but also a great challenge to translate evidence-based 
knowledge into practise, the so-called ‘know-do gap’.109 The environment for 
midwives in low-resource settings is challenging for the translation of knowledge into 
practise. A Cochrane review in 2017 looked at factors influencing the provision of 
intrapartum and postpartum care by skilled birth attendants in low- and middle-
income countries.55 The ability of midwives to provide quality care was limited by a) 
lack of training both in their pre-service and in-service education, b) lack of 
equipment, and c) not the least, time. Access to training and supervision, well-
equipped, well-organised healthcare facilities would save lives and take us closer to 
the SDG 3.2 goal. 
2.1 Mobile health and smartphone apps 
While a standardized definition of mobile health (mHealth) has not yet been 
established, the WHO uses the following definition: “mHealth or mobile health is 




medical and public health practice, supported by mobile devices, such as mobile 
phones, patient monitoring devices, personal digital assistants, and other wireless 
devices. mHealth involves the use and capitalization on a mobile phone's core utility 
of voice and short message service, as well as more complex functions, including 
general packet radio service, third and fourth generation mobile telecommunications, 
global positioning systems and Bluetooth technology”.110  
Mobile health can be used to support health-related tasks, such as monitoring, data 
collection, education and consultation. This strategy is increasingly used in low-
resource settings where mHealth can extend the reach of health services and is 
becoming a formal part of healthcare. The number of mobile phone users is 
expanding quickly and was expected to pass 4.68 billion in 2019.111 The widespread 
use of mobile phones highlights the significant opportunities to have a global impact 
on health behaviour, and midwives are encouraged to be involved in the mHealth 
revolution.112 To include midwives in the development of relevant and functional 
apps is essential to get apps suitable for the clinical context in low-resource settings. 
A significant proportion of health personnel in low-resource settings have their own 
smartphone, the number increasing, giving us the idea of using a tool that the health 
workers already have.111,113 
2.2 Development of NeoTapLS (Life Support)  
Tap4Life is a registered non-profit organization based in Stockholm, Sweden (reg. 
no. 802495-5216) started by members of our research team. The project started as 
part of a research project in Uganda involving Makerere University (Uganda), The 
Centre for International Health (Norway) and the Karolinska Institutet (Sweden).114 
The lack of reliable monitoring equipment for neonates in the delivery room lead to 
the development of the first prototype for point-of-care HR registration by Michael 
Vaganov, a software engineer from California, and was further developed with a 
grant from Innovationsfonden, Region Stockholm, in 2014. With further funding 
Tap4Life has continued this development with constant feed-back from users both 
during the observational studies and the trial presented in this thesis.  





The mission of Tap4Life is to improve healthcare by the development of mHealth 
applications, freely downloadable on Google-play and App-store. The Tap4Life team 
is at present focusing on neonatal mortality and morbidity in low- and middle-
resource settings and doing research on their products to assess their quality and 
feasibility in clinical use. NeoTapLS (Life Support) produced by Tap4Life (Figure 
6)115 is based on a screen-tapping method, no probes needing to be attached to the 
neonate. The interface is designed to be visible even if a latex glove protects the 
phone. Health personnel even in remote areas will be able to use their phone as a tool 
that may improve performance in the immediate care of neonates. 
 
Figure 6. a) Tap to record the neonate’s heart rate by the NeoTapLS application. 
Heart rate <100 bpm (yellow) at 37 s: prepare for ventilation.  
b) Heart rate <60 bpm (red) at 2 min and 11 s: start chest compressions? c) Heart 
rate ≥100 bpm (green) at 3 min and 37 s: neonatal resuscitation is going well. 
Published with the kind permission of Tap4Life. 
A major feature of NeoTapLS is the algorithm-based screen-tapping assessment of 
HR. The user auscultates the heart sounds or feel the pulse and taps the beat on the 
screen a minimum of 3 times from which the app generates a number. The NeoTapLS 
calculates the HR based on the user’s last 3 taps on the smartphone screen and 
bypasses the need for any mental arithmetic. This algorithm can also be used to 




monitor foetal HR. An instructional video on ‘How to use NeoTapLS’ is available on 
YouTube.  
The features of NeoTapLS have evolved over the years after feedback from users and 
video analysis on how it is used. The present version of NeoTapLS, used in article II, 
has the following features:  
• Pop-up messengers on important aspects of neonatal resuscitation 
• Prepare for birth – checklist for tools important for neonatal resuscitation 
• Oral and written messages for guidance through the resuscitation 
• Colour-coded foetal HR  
• HR and Breathing Rate registration within 10-15 s after birth, colour-coded 
according to HBB guidelines  
• Resuscitation timer 
• Automated Apgar score calculation 
• NeoPacer – pacing the recommended ventilation pace by sound, visual 
feedback and vibration 
• Tracking of vital events 
• Identification of danger signs 
• Referral decision support 
• Tutorials on the cornerstones of neonatal resuscitation: 
o prepare for birth 
o the art of resuscitation 
o stimulation 
o suction  
o ventilation and more 
 
NeoTapLS is now freely available on Google Play and App Store. A free-of-charge 
iPad version, NeoTapAS (Advanced Support), for high-resource settings is also freely 
available. Both apps have the tapping function for HR.  
  





2.3 Respiratory support worldwide 
International guidelines on neonatal resuscitation are currently unanimous that PPV 
should be initiated within 60 s after birth in neonates requiring PPV.17,19,91 This gives 
the carer limited time to determine the state of the neonate by physical examination, 
including measurement of HR. Prompt initiation of PPV is critical to the outcome. In 
2012 it was shown that an increased risk of prolonged hospitalization and death 
occurs of 16% for every 30 s delay in initiating PPV using face-mask ventilation 
(FMV).2 The United Nations Commission on Life-Saving Commodities for Women 
and Children in 2012 started with the goal of increasing access to life-saving 
medicines and health supplies for people living in low-resource settings. They 
produced a list and indicated efforts needed to increase access to 13 essential 
commodities, including neonatal resuscitation equipment (mask, valve and bag).116  
2.3.1 The bag of air 
Mouth-to-mouth resuscitation has been used since biblical times as a technique using 
one’s own lungs as a reservoir of air to breath into the mouth of the non-breathing 
neonate.117 In some settings, mouth-to-mask resuscitation remains in use. Most 
settings today use devices for the same purpose. To have good equipment is essential 
in minimizing the risk of mask leakage, excessive pressures and volumes causing 
pneumothorax (collapsed lungs). A self-inflatable bag is the most common way to 
provide PPV and create functional residual capacity in low-resource settings. Bags 
can be for both single and multiple use. New inventions, such as the Upright 
Resuscitator (Laerdal, Stavanger, Norway), have been introduced recently, and good 
quality bags are sold at a low price.116,118,119 The reusable, high quality NeoNatalie 
Resuscitator (Laerdal, Stavanger, Norway; Figure 7) is most often administrated with 
the HBB kit, and has also been used in studies included in this thesis. The size of the 
lungs differs with the size of the neonate, which must be remembered, especially 
when delivering PPV to preterm neonates. Tidal volume - the normal inhaled and 
exhaled volume of air- of preterm and term neonates ranges from 6.5 to7 ml per kg, 
and a tidal volume from 4 to 8 ml per kg is recommended during resuscitation with 
40-60 breaths per min.17,19,91,120 A bag size for neonates of <5 kg is recommended to 









Figure 7. NeoNatalie Resuscitator including 2 face masks. Published with the kind 
permission of Laerdal Global Health. 
2.3.2 Face-mask ventilation (FMV) 
FMV can be a lifesaving intervention; it is a proven technique and may in 
emergencies be as effective as endotracheal intubation (placing a tube in the 
windpipe), if administered properly. It has been estimated that FMV could reduce 
intrapartum related death by 40%.121 However, it is a difficult task, with mask 
leakage and poor chest movements being reported.122-124 The most common round 
mask with a soft rim must create a good seal, and the bag must be of the right size 
and undamaged. Difficulties in achieving proper FMV may be due to upper airway 
obstruction.125 Clearing the airway, repositioning the mask, opening the mouth or 
increasing the pressure may resolve these problems, but in the case of failure one 
needs to consider an alternative airway as an endotracheal tube (ETT) or a laryngeal 
mask airway (LMA).  





2.3.3 Endotracheal tube (ETT) 
During cardiopulmonary resuscitation, FMV is normally the first choice for 
administrating air into the lungs, followed by ETT if neonatal depression 
continues.126 ETT insertion is difficult and requires a laryngoscope and a trained 
doctor; it is often impossible to perform in low-resource settings.127 Improper 
management can cause damage to the neonate, such as laryngospasm and subglottic 
trauma, and may cause cardiopulmonary failure.16  
2.3.4 Laryngeal mask airway (LMA) 
The LMA was designed and also produced by Archie Brain, who published the first 
article in 1981.128 The aim was to produce an airway device more effective than the 
FM and less invasive than the ETT, without the need for a laryngoscope and with 
minimal instrumentation of the larynx.126 LMA causes fewer side effects than ETT in 
paediatric surgical procedures.129 LMAs are used in anaesthesiology during surgical 
procedures both for adult and children. It is also used in pre-hospital resuscitations by 
paramedics because it is easy to use. LMAs are today also referred to as ‘laryngeal 
mask’ or ‘supraglottic device’, and as the LMA in this thesis. ILCOR 2015 states that 
an LMA during neonatal resuscitation may be considered as an alternative to FM for 
neonates weighing >2000 grams or delivered around or after 34 weeks of 
gestation.17,18,20 The LMA can be used with a standard self-inflatable bag or a T-piece 
resuscitator. The cuffed LMA (Figure 8) has a pre-curved cuff and is placed blindly 
along the palate of the neonate until it stops at the top of the oesophagus, creating a 
seal. After placement, the cuff is inflated according to size of the neonate. In the 
Democratic Republic of Congo, training in inserting a cuffed LMA on manikins with 
midwives and physicians was highly successful in a short time.130 Newer, more user-
friendly, devices have been developed that do not need to be cuffed (Figure 8d). 
Previous studies showed that the LMA facilitated effective PPV, but currently there is 
limited evidence of its use; the use of LMA in neonatal resuscitation needs further 
investigation.131 LMAs ease of use shows it is suited for non-doctoral health 
personnel in low-resource settings.  




Figure 8. a) LMA ClassicTM b) LMA SupremeTM c) LMA ProSealTM d) i‐gel®                      
e) Ambu®AuraOnceTM f) Air‐Q. g) ShileyTM. Published with the kind permission of 
Karger publishers. 
2.3.5 Uncuffed LMA: The i-gel® 
The i-gel LMA (Intersurgical Ltd, Wokingham, Berkshire, UK; Figure 8d) was 
introduced in 2007 and is now widely used for surgery requiring general anaesthesia. 
This cuffless, latex-free, single-use LMA has an interface made of a soft gel-like 
transparent thermoplastic elastomer. The material produces a light pressure on the 
pharyngolaryngeal structure, producing a good seal without the cuff (Figures 9 and 
10).132 I-gel is easy to place because of its small size and precurved shape; one study 
showed reduction of the insertion time from 18 to 13 s compared to a cuffed LMA.133  
 






Figure 9. The i-gel from 2 angles and the Laerdal face mask. Photo: T. Tylleskär. 
 
Figure 10. Anatomical transect showing the position of the i‐gel. Published with the 
kind permission of Intersurgical. 




2.4 Prior research  
Previous manikin studies with LMA showed that a brief training on a manikin gave a 
100% success rate, and the LMA was well received by non-doctor users even in low-
resource settings.134-136 In 2016, our team compared the performance of health 
personnel in Uganda when using an LMA or a FM on a manikin.137 The study again 
reported a 100% success rate on first insertion with the LMA. FM was significantly 
less effective in achieving effective PPV, and the failure rate at the first attempt was 
28%. This drew us to the conclusion that LMA would be more effective than FM in 
establishing PPV. 
In 2014-15, we conducted a phase II trial on the safety of i-gel in the hands of 
midwives in Uganda, ClinicalTrials.gov Identifier: NCT02042118. Neonates needing 
PPV were randomized to either i-gel LMA or FM. This prospective, observational 
study on 49 neonates (24 in the LMA and 25 in the FM arm) had a success ratio of 
100% for the insertion of i-gel.114 The study showed no adverse events (AEs), shorter 
ventilation time, quicker pick-up of HR and fewer admissions to the NICU in the 
LMA arm (Table 2). In short, these are very encouraging results. 
 
Table 2. Overview of results from our phase II trial in Uganda 2014-15.114    





Ventilation time in seconds mean(±SD)   93 (52) 140 (90) p=0.02 
Heart rate at  90 seconds (±SD)   148 (39)  127 (45) p=0.07  
Heart rate at 120 seconds (±SD)   161 (33) 134 (49) p=0.01  
Heart rate at 180 seconds (±SD)   167 (26) 143 (36) p=0.01  
Assistance from supervising physician   3 6 p=0.46 
Admission to the neonatal unit   5 8 p=0.52 
Hypoxic ischemic encephalopathy  0 2 p=0.49 
Adverse events related to ventilation   0 0  
Deaths at 24 hours   0 0  
 
  





2.5 Rationale  
As discussed above, innovations and new strategies have the potential to improve the 
outcome of neonatal resuscitation; reaching the SDG 3.2 now needs our full attention. 
Targeting low-resource settings with the highest mortality rates and implementation 
of evidence-based interventions could prevent many early neonatal deaths and 
decrease morbidity in surviving neonates. 
HR assessment is a very important clinical parameter in neonatal resuscitation and is 
often performed nowadays by midwives in low-resource settings. They still lack 
training and equipment, creating a barrier to optimal performance. Research on HR 
assessment during neonatal resuscitation, including midwives in low-resource 
settings, has not yet been carried out, which could improve outcomes. The need to 
develop a low-cost, rapid and accurate alternative to HR monitoring during neonatal 
resuscitation has been emphasised.89,92 
Neonatal resuscitation with uncuffed LMA has been investigated by our team, but the 
benefit in terms of mortality and morbidity remains unknown.114,137 Our studies 
indicate a beneficial effect in the short-term and the ease-of-use of the LMA in the 
context of neonatal resuscitation in low-resource settings. Before this thesis, no large 
studies designed to assess mortality and morbidity had been carried out. PPV is the 
single most important component of successful neonatal resuscitation.17,19,91,119 
Effective PPV has the potential to reduce by 40% intrapartum-related deaths.65,138-141 
The effectiveness and safety of LMAs compared to FM as the primary device for 
neonatal resuscitation have still to be fully assessed. Task-shifting the use of LMAs to 
non-doctors could be one way of improving the outcome.  
  




3 Aim and objectives 
The overall aim of this thesis has been to explore whether innovations and new 
strategies could improve neonatal resuscitation practices, and thereby reduce 
mortality and morbidity in a low-resource setting.  
The specific objectives were: 
I. To determine if health personnel could randomly determine selected simulated 
heart rates on a Laerdal SimNewB manikin by auscultation or palpation, using 
the NeoTapLS (Life Support) application (article I) 
II. To assess the NeoTapLS app in 3 phases (article II): 
a. In phase one, a metronome rate recorded by low-end users (midwives)  
b. In phase two, heart rate in neonates not needing positive pressure 
ventilation recorded by high-end users (paediatricians) using NeoTapLS 
versus pulse oximetry  
c. In phase three, heart rate in neonates needing positive pressure 
ventilation recorded by low-end users using NeoTapLS versus 
electrocardiography 
III. To assess in a phase III open-label superiority randomized controlled clinical 
trial the effectiveness and safety of the laryngeal mask airway versus face-
mask ventilation in neonatal resuscitation in reducing early neonatal death and 










4 Subjects and methods 
This thesis consists of 2 observational studies (articles I and II) and one clinical trial 
(article III). The observational studies include both simulations and clinical 
assessments on neonates. The setup of the phase III trial, the Neonatal Supraglottic 
Airway Trial (NeoSupra Trial) was used to collect data for article II, phase three. 
Phase III refers to a study that tests the safety and how well a new treatment works 
compared with a standard treatment. In most cases, treatments move into phase III 
clinical trials only after they meet the goals of a phase II clinical trials. A phase II 
trial has been performed prior to the NeoSupra Trial.114 Phase II and III in this thesis 
should be differentiated from phase two and phase three (article II). 
4.1 Article I and II - assessing NeoTap Life Support (NeoTapLS) 
Article I and II assessed the NeoTapLS application. The hypothesis was that 
NeoTapLS was faster than pulse oximetry and ECG, and accurate enough to follow 
neonatal guidelines. The findings could be important for low-resource settings where 
pulse oximetry and ECG are rarely available. Providing NeoTapLS in a low-resource 
setting inexpensively support HR assessment, but it also needs to be feasible to use in 
environments where most neonatal resuscitations are done by non-doctoral health 
personnel.  
4.2 Article III, the NeoSupra Trial 
The hypothesis in the NeoSupra Trial was that effective PPV would be easier to 
achieve with an LMA than with a FM, with the potential of decreasing early neonatal 
death and moderate-to-severe HIE. The findings could be important for low-resource 
settings where the majority of intrapartum-related events occur. Providing LMA in a 
low-resource setting is expensive; it can only be justified if there is a substantial gain 
in using the LMA over the standard of care FM. Based on our prior phase II trial, we 
estimated that early neonatal death and moderate-to-severe HIE could be reduced by 
25%, a difference large enough to have policy implications.114,142 The trial protocol 
followed the SPIRIT guidelines and has been published.142  




4.3 Study settings  
Article I was conducted at Sachs´ Children and Youth Hospital, Stockholm South 
General Hospital, Stockholm, Sweden (Figure 11). The hospital has the largest 
emergency care unit in the Nordic region. The paediatric emergency unit provides 
care services to neonates, children and young adults up to 18 years of age. The 
hospital operates one of the largest maternity clinics in Sweden, providing excellent 
opportunities for clinical research (Table 3).  
 
Figure 11. Sachs´ Children and Youth Hospital, Stockholm South General Hospital, 
Stockholm, Sweden. Published with the kind permission of Södersjukhuset AB. 
Article II and III were conducted in Uganda at the High-risk Labour Ward and 
Operating Theatre, Department of Obstetrics and Gynaecology, Mulago National 
Referral Hospital, Kawempe, Kampala, connected to the Makerere University (Figure 
12).114 The hospital also serves as a general hospital for Kampala, a fast-growing 
area. The Kampala city population was 62 000 in 1948 and had grown to 1.5 million 
inhabitants by 2014, with the Kampala metropolitan area having ~4.5 million (Table 
3).143 The Kawempe division opened in 2016 and the hospital changed its name in 
2019 to Kawempe National Referral Hospital. It is currently home to the Directorate 
of Obstetrics and Gynaecology and the NICU. In 2018 the Kawempe division had 
~25 000 deliveries and ~60% were referred to the hospital from other health facilities 
due to complicating factors. 






Figure 12. Mulago National Referral Hospital, Kawempe division, Kampala, Uganda. 
Photo: T. Tylleskär. 
The University of Bergen and Karolinska Institutet have long-lasting academic 
collaborations with Makerere University, and have conducted a number of studies 
within the field of neonatal resuscitation and HIE reporting and classification (Figure 
13).101,102,106,114,137,144 These studies report a high rate of HIE after intrauterine insults 
and birth asphyxia, as well as the need to improve HBB training.145  
Uganda has a high rate of neonatal mortality. From 2000 to 2006 there was a small 
decrease (from 33 to 27 deaths per 1000 live births), but since then it has remained 
unchanged.146 Neonatal mortality, as in the rest of the world, has come to constitute a 
larger proportion of neonatal and under-5 years mortality. 





Figure 13. Mulago National Referral Hospital also housing College of Health Sciences 
of Makerere University. Photo: T. Tylleskär. 
Table 3. Information about the 2 hospitals involved in article I-III 
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Recruitment for the trial (article III) was done from 2 resuscitation tables in the 
operating theatres and one resuscitation area in the delivery suite, all without 
warmers. Around 150-200 midwives and doctors participated in the obstetric care at 
the hospital and took part in the study. Research assistants (RA) and a supervisor 
were present 24/7 at the resuscitation area. The health personnel had clinical 
experience of ventilating neonates with a FM and were introduced to the LMA as part 





of the trial.114 Suction bulbs and self-inflating bags with masks (Laerdal, Stavanger, 
Norway) were always available. ETT was rarely carried out due to lack of skills and 
adequate equipment. Intravenous fluids were delivered through peripheral 
intravenous lines on rare occasions. Embrace Nest™ (Phoenix Medical Systems, 
India) infant warmer for transport of neonates and pulse oximetry for monitoring 
were available on site but were mostly out of order. The setup of equipment was 
equal to our previous trial at the study site, but with new suction devices (Penguin 
Suction Device,  Laerdal, Stavanger, Norway) for easier cleaning. New standardized 
cleaning processes of  equipment were introduced, done by RAs on a daily basis. 
At the time of the trial, the capabilities/available services of the Mulago National 
Referral Hospital NICU were as follows:  
• Free flow oxygen, CPAP, and self-inflating bags and masks for resuscitation. 
There were no ventilators 
• Pulse oximeters were available, but not enough for monitoring all sick 
neonates in need. Health personnel had to identify neonates to put on 
continuous monitoring and others had intermittent checks of their oxygen 
saturation  
• Availability of parenteral fluids were as follows: dextrose, Ringer’s lactate, 
normal saline. No total parenteral nutrition 
• The anticonvulsants available were: intravenous phenobarbitone, used as the 
first line according to the national guidelines, and phenytoin as second line  
• Antibiotics in use were: ampicillin, gentamicin, cefotaxime and ceftriaxone  
• Blood tests available were: complete blood counts, serum electrolytes, liver 
function, renal function, blood grouping and cross-matching  
• Not available: aEEG monitoring or therapeutic hypothermia  
• There was no space for continuous Kangaroo Mother Care, which was done 
intermittently when neonates were admitted  
  






With the aim of covering a wide range of existing or non-existing clinical skills, the 
participants were recruited from a variety of professional and educational 
backgrounds. None of them had previous experience in the NeoTapLS app and all 
those we approached agreed to take part in the study. We disregarded prior 
experience in smartphone management (Table 4).  
Article II 
In phase one and three we involved low-end users (midwives). In phase two we 
involved high-end users (paediatric specialists) (Table 4 and Figure 14). These were 
sub-studies of our previous trial on LMA versus FM114 and the NeoSupra Trial 
(article III). 
 
Figure 14. Setup for article II phase two. Photo: T. Tylleskär. 





Article III  
The inclusion criteria of this trial were as follows: neonates born in the hospital, with 
parental consent, estimated gestational age ≥34 weeks and/or estimated birth weight 
≥2000 gram, requiring PPV at birth. Neonates with major malformations and 
stillbirths did not fulfil the inclusion criteria (Table 4).  
Table 4. Design and participants  
 Design Participants Recruitment 
Article I Observational simulation 
manikin study, testing the 
NeoTapLS app using a Laerdal 
SimNewB manikin that 
simulate heart rates  
 
30 participants:  
8 doctors, 6 nurses,  
3 nurse assistants,  
6 nurse students,  
2 medical students,  









Article II Prospective observational 
study in 3 phases assessing 
rates and heart rates with the 
NeoTapLS app  
Phase one: NeoTapLS 
compared to a metronome 
Phase two: NeoTapLS 
compared to pulse oximetry 
Phase three: NeoTapLS 
compared to ECG 
Phase one and three:  
18 low-end users 
(midwives) 
Phase two: Two high-
end users (paediatric 
specialists) 
 
May, 2015, to 





Article III Phase III open-label 
superiority randomized 
controlled clinical trial to 
compare the use by midwives 
of a laryngeal mask airway 
with face-mask ventilation 
1163 asphyxiated 
neonates 
May 8, 2018, to 





4.5 Equipment and data recording  
4.5.1 NeoTap Life Support (NeoTapLS) 
In articles I and II, we investigated the use of NeoTapLS. During neonatal 
resuscitation HR gives feed-back on the effect of resuscitation efforts, as well-
functioning ventilation raises the HR in almost all asphyxiated neonates. It is critical 
to be able to measure HR in both foetuses and neonates. However, HR assessment is 
not easy and studies show that the evaluation often is inaccurate.81,82,84,88,89,92,95,147-150 




A significant proportion of health personnel in low-resource settings have their own 
smartphone.111,113 RAs and study doctors of the NeoSupra Trial received phones 
preloaded with a beta software version of NeoTapLS during the data collection of 
article II phase one and three. This allowed us to get feedback on the interface and 
the design of the app.  
In article II phase three, the use of NeoTapLS allowed intermittent assessment of the 
HR during resuscitation with the output being visible on video recordings.  
4.5.2 SimNewB®  
The SimNewB (Laerdal, Stavanger, Norway) manikin used in article I is an advanced 
manikin designed to help improve neonatal resuscitation (Figure 15). It generates 
both breathing and simulated HRs, providing realistic training. An extensive ECG 
Library in the computer attached to the manikin can produce cardiac-, umbilical- and 
brachial- simulated HRs from 10 to 300 bpm. 
 
Figure 15. Participant auscultating the precordium of the manikin and at the same 
time tapping the screen of the smartphone with the NeoTapLS application. Photo: S. 
Myrnerts Höök, the participant agreed to this publication. 





4.5.3 NeoNatalie™ and Newborn Anne™ 
We used 2 training manikins in training for the NeoSupra Trial. NeoNatalie (Laerdal, 
Stavanger, Norway) is an inflatable manikin included in the HBB training kit (Figure 
16a). It has been developed to provide the needs in teaching the initial steps of 
resuscitation. The operator can manually simulate breathing movements and HRs on 
the manikin. The Newborn Anne™ (Laerdal, Stavanger, Norway) neonatal baby 
simulator has been used in training LMA insertion (Figure 16b). It is designed for 
training in neonatal airway management, including the use of positive-pressure 
airway devices, and the placement of LMA and ETT. 
                a                  b 
 
Figure 16. a) Face-mask ventilation training with NeoNatalie™ according to the 
Helping Babies Breathe 2nd edition. Photo: S. Myrnerts Höök.  
b) Insertion of LMA training with Newborn Anne™. Photo: N. Pejovic. 
4.5.4 Metronome 
In article II phase one, a metronome app (Metronome; Beijing Buluobang Co, Ltd.) 
was used to generate audible metronome rhythms. It is the world´s most famous free-
of-charge metronome app generating exact rhythms. Random rates generated for the 
participants, selected using a number generator sets over the range of 20–150 bpm.151 
4.5.5 Pulse oximetry  
In article II phase two, pulse oximetry (PalmSAT 2500, Nonin Medical, Plymouth, 
USA) was used as the true value since no other monitoring equipment was available 
at the time (Figure 17). It is a small, handheld pulse oximeter designed to accurately 
assess peripheral capillary oxygen saturation and pulse rate.  






Figure 17. Two heart rate assessment methods in use. The first generation NeoTapLS 
(background left), showing a heart rate of 174 bpm and pulse oximetry (PalmSAT 
2500, Nonin Medical, Plymouth, USA, background right), showing a heart rate of 176 
bpm. Photo: T. Tylleskär, with the kind permission of the parents. 
4.5.6 Electrocardiography (ECG) 
In article II phase three, the first 49 data collected from NeoTapLS were compared to 
traditional ECG (Philips Intellivue X2, Amsterdam, The Netherlands), a combined 
multi-measurement module and transport monitor (Figure 18). The ECG was put on a 
neonates directly on arrival to the resuscitation table. 
4.5.7 Dry-electrode Electrocardiography (ECG) 
In article II phase three, the last 186 data collected from NeoTapLS were compared 
to dry-electrode electrocardiography, NeoBeat Newborn HR Meter (Laerdal, 
Stavanger, Norway; Figure 18). It is a reusable and easy-to-use HR meter providing 
continuous display of neonatal HR. NeoBeat was put on a neonate’s abdomen on 
arrival at the resuscitation table and displayed the HR within s. NeoBeat uses dry 
electrodes to pick up an ECG-based signal, making it comparable to conventional 
ECG.  







Figure 18. NeoBeat dry-electrode electrocardiography (left), showing a heart rate of 
63 bpm, conventional ECG with a heart rate of 63 bpm (right, in green numbers), and 
NeoTapLS (middle) with a heart rate of 68 bpm. Photo: S. Myrnerts Höök, with the 
kind permission of the parents. 
4.5.8 Video monitor  
In the NeoSupra Trial (Article III), we video-recorded all resuscitations with a HD 
1080P Black box AI-IP018 camera (Shenzen Aishine Electronics Co. Ltd, China) 
attached above each of the 3 resuscitation tables (Figure 19). The same setup had 
been used for data collection for Article II phase three. The view of the camera was 
adjusted to show only the neonate and the hands of the health personnel. The cameras 
were small and well disguised, and our impression was that the health personnel 
forgot about the cameras within days, and thus it did not affect their performance.  





Figure 19. Setup at one of the resuscitation tables with the Mulago Hospital 
Resuscitation Flow Chart (Annex II), Apgar scoring reminder and note showing 
randomization of the day on the wall. The camera is hidden behind the warmer 
above the table. Photo: S. Myrnerts Höök. 
4.6 Training  
Article I 
The participants, disregarding previous knowledge of NeoTapLS or smartphones, 
were introduced to the setup of the NeoTapLS and the Laerdal SimNewB simulation 
manikin for 3-5 min. The patient simulator was used for all simulations and is 
capable of generating heart tones as well as umbilical and brachial pulsations. The 
instructions were to determine the simulated HR by auscultation of the precordium or 
palpation of the brachial pulse of the manikin, and simultaneously tap the pace they 
heard or felt on the screen of a smartphone a minimum of 3 times, with the 
NeoTapLS app installed. They were also instructed to say ‘stop’ when they had 
generated a number they were relying on.  






The midwives in article II phase one and three were trained within the framework of 
the NeoSupra Trial, as explained below. The midwives, disregarding previous 
knowledge of NeoTapLS or smartphones, were introduced to the NeoTapLS app for 
3-5 min. The instructions in phase one were to determine the rate of a metronome by 
listening to the sound and simultaneously tap the pace they heard on the screen of a 
smartphone a minimum of 3 times, with the NeoTapLS app installed. They did not 
receive any further training before the data collection in phase three. The paediatric 
specialists in phase two were well familiar with NeoTapLS and had used it prior to 
the study. They did not receive further training before data collection started.  
Article III  
A one-day extended and modified HBB course (2nd edition) were held involving all 
midwives regularly exposed to performing neonatal resuscitation (~150 persons).68 
This training included FMV practice and a module for use of LMA in a manikin 
(SimNewB). From 20 to 25 participants and 4-5 facilitators (2 paediatricians and 
local HBB instructors) participated in each session (Figure 20). We used 7 
NeoNatalie inflatable manikins and 2 SimNewB manikins. Two NewLifebox-R 
(Advanced Life Diagnostics, Weener, Germany) neonatal respiratory function 
monitors were used to optimize training in ventilation, giving objective feed-back on 
respiratory rate, airway leakage (%), peak inspiratory pressure (cm H2O) and tidal 
volumes (ml per kg). Three successful LMA insertions combined with adequate 
chest-rise in the manikins were required of each participant. Suction practice was de-
emphasized. HBB 2nd edition courses to new providers and refresher courses were 
held throughout the trial. 
Doctors involved in daily Thompson scoring of neonates at the NICU, who had 
already received and practiced the scoring system in a previous study,106 were given a 
refresher course prior to start of recruitment. The severity of asphyxia was based on 
the Thompson score used to assess signs of HIE.103,105 
 





Figure 20. Midwives certified after the modified HBB 2nd edition course, including the 




Recruitment for the NeoSupra Trial continued around the clock from May 8, 2018, to 
August 12, 2019, with a short interruption of a few weeks during May-June 2019. 
The resuscitations were carried out on 3 resuscitation tables at different locations in 
the hospital and could coincide with each other. Because of the nature and emergency 
of neonatal resuscitation, it was not feasible to randomize every birth potentially 
requiring resuscitation of the neonate. To manage this challenging setup, we chose 
day-by-day cluster randomization with the help of an independent statistician, using 
randomly selected block sizes of 4 to 8. The block sizes were determined by the 
number of arms, meaning that block size had to be divisible by the number of 
treatment arm, in this case 2. In this trial, block sizes of 4, 6 and 8 were randomly 
selected. This block randomization method is designed to generate equal sample sizes 





in the different arms, at the same time making it difficult to anticipate the next 
randomization arm. 
All neonates enrolled each day (defined as 08:00 am to 8:00 am the following day) 
were randomized for the same treatment. The randomization was concealed in sealed 
and dated envelopes. A new envelope was opened each morning at 8.00 am by an RA 
who also checked the 3 resuscitation tables, adjusted the signs and changed to the 
device for the day at the tables (Figure 21). The device not assigned for the day was 
available in a sealed box next to the resuscitation table, if needed to improve 
ventilation. The instruction was to continue ventilation for 3 min with the device of 
the day and, if chest rise was inadequate, to reposition the LMA or reapply the FM 
before considering switching. When switching occurred, a report had to be filled in 
explaining the reason. The decision to allow a switching of device in the trial was 
based on ILCOR recommendations.17,18,20  
 
Figure 21. Opening of the first concealed envelop of NeoSupra Trial 8th in May 2018. 
Photo: S. Myrnerts Höök; the research assistant agreed to the publication of the 
photo. 




4.8 Data collection and management  
Article I 
In this manikin study, data were collected and managed by me referred to hereafter as 
the researcher. I was a residential doctor in paediatrics at the time. Before starting a 
scenario, the manikin was programmed with a randomly generated simulated HR and 
had no active respiration.151 The researcher told the participant to start measuring the 
rate and simultaneously started a stopwatch. When the participant had generated a 
number thought to be right, they said ‘stop’. The researcher stopped the stopwatch 
and asked the participant for the number displayed on the NeoTapLS screen. 
Acquisition time, defined as the time from start to stop, and the number on the 
NeoTapLS screen were noted for all scenarios. The data were transferred to an Excel 
file at the end of the day.  
Article II  
In this prospective observational study in 3 phases, data were collected and managed 
by the researcher, a paediatric specialist at the time.  
In phase one, rates were randomly selected using a number generator set in the range 
of 20–150 bpm,151 and presented by a metronome, masked to the participants. The 
rates were presented for ~20 s. The participants recorded the rate with the NeoTapLS 
and wrote down the number on separate papers collected by the researcher at the end 
of each session, and the data were again transferred to an Excel file.  
In phase two, pulse oximetry was placed on the neonate on arrival at the resuscitation 
table by one high-end user (a neonatologist) and HR was assessed using NeoTapLS 
by the second high-end user (the researcher) as soon as the HR was displayed on the 
pulse oximeter. Directly after HR was assessed using NeoTapLS, the second high-
end user checked the HR on the pulse oximeter (unmasked) and noted both HRs. 
Acquisition time of NeoTapLS was noted (defined as s from start to end of tapping). 
Data were collected on-site when high-end users were available, before being 
transferred to an Excel file.  





In phase three, ECG was placed on the neonate by the researcher or an RA when 
feasible directly after arrival at the resuscitation table. HR was assessed by low-end 
users (midwives) using NeoTapLS once HR had been displayed by ECG and 
compared with HR obtained  simultaneously by ECG (not masked to the 
participants). The midwives continued to monitor HR with the NeoTapLS as many 
times as they thought appropriate for the clinical situation. All paired HRs (HR by 
NeoTapLS at the same time as HR by ECG) until end of resuscitation were collected. 
The acquisition time of NeoTapLS was noted. The first 49 HR data were supervised 
by the researcher and collected on-site by conventional ECG (Philips Intellivue X2, 
Amsterdam, The Netherlands), the data being recorded for transfer to an Excel file at 
the end of the day. The following 186 HR data were unsupervised and collected from 
video review compared with dry-electrode ECG (NeoBeat) and entered directly into 
an Excel file. Data were collected each day from the camera memory card and 
transferred to 2 separate hard drives. Data on Apgar and weight were collected from 
the Case Report Forms (CRF) of the NeoSupra Trial (Annex I) and double-entered 
using Android devices running the Open Data Kit V.2.0 tool suite.152 
Article III  
In this phase III open-label superiority randomized controlled clinical trial, the 
NeoSupra Trial, data were collected and managed by a team. This team consisted of 
one trial manager, 3 investigators, 3 doctors at the NICU, 18 RAs and 2 data entry 
managers. RAs were on site for 24/7, recording with a stopwatch time from birth to 
arrival at the resuscitation table. At arrival the neonates were filmed, and the data 
could be retrieved by video review. However, observations during resuscitation were 
timed by the RAs with a stopwatch in case of video failure. Data was collected each 
morning from the 3 camera memory cards and transferred to 2 separate hard-drives. 
Ventilation time was double-checked by video review each morning. Videos could 
also show if the neonate was in fact breathing and there was no need for PPV, in 
which case the information was excluded. Assistance by supervising physician, 
advanced interventions, e.g. CPR, and any switch to an alternative device could also 
be reviewed on videos.  




Data from mothers and neonates were collected bedside from clinical charts and 
interviews on day 0 by the RAs and filled into pre-coded CRF 1 and 2 (Table 5 and 
Annex I). The CRFs were reviewed daily by the local trial manager for quality 
control. Weekly meetings were held with the RAs to discuss the data and correct 
deviations from the Standard Operational Procedure. Doctors at the NICU assessed 
neonates on their Thompson score on days 1-5 and filled a daily CRF 3 (Annex I).103 
CRF 4 was filled by research NICU doctors, RAs or the local trial manager on day 7 
or above (Annex I). Data were double entered into Open Data Kit (ODK, 
https://opendatakit.org) by the 2 data entry managers from the paper CRFs and 
transferred to an encrypted server. Data-cleaning was managed by the researcher, and 
data were also corrected after review of videos and scanned CRFs. The clean data-set 
was transferred to R software version 3.5 (R Foundation for Statistical Computing, 
Vienna, Austria)153 for final analysis.  
Table 5. Timeline of the participants in the NeoSupra Trial. 
 Day 
0 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Prior consent  X        
Deferred consent   X       
Randomisation  X        
Monitoring of resuscitation  X        
Video recording  X        
Id-bracelet infant and mother  X        
Filling CRF part 1  X        
Filling CRF part 2  X        
Thompson score (if admitted) 
CRF part 3 
(X) (X) (X) (X) (X) (X)   
AE, SAE assessment   X  X  X  X  X  X  X  X 









4.9 Statistical analysis 
4.9.1 Article I 
Stata Statistical Software version 14.0 (StataCorp LP, College Station, Texas, USA) 
was used to analyse the results of article I. Numerical variables were summarised 
with means, ranges and standard deviations, and categorical variables were 
summarized using frequencies. To compare correlations between numerical variables, 
Pearson´s correlation coefficients were estimated. Results were presented with 95% 
confidence intervals. Since the data were clustered within individuals, all the 
inferential analyses were adjusted to take into account its clustered nature. P <0.05 
were considered significant. 
4.9.2 Article II 
Agreement in phase one was assessed using a Bland-Altman plot (including 
Pearson´s correlation coefficients between HR difference and HR values). Agreement 
in phase two and three was assessed using a Bland-Altman plot for repeated measures 
(including repeated measure correlation between HR difference and HR values), and 
in phase three using repeated measures version of kappa index on the following HR 
categories: less than 60, 60–99 and 100 bpm or above. The sensitivity and specificity 
of NeoTapLS in detecting bradycardia (HR less than 100 bpm) were also calculated. 
Acquisition times in phase two and three were summarized with median and inter-
quartile range (IQR) for descriptive purposes. Statistical analysis was performed 
using R V.3.5 (R Foundation for Statistical Computing, Vienna, Austria).154  
4.9.3 Article III  
A 25% reduction in the primary outcome measure was considered to be clinically 
relevant for changing clinical practice. A sample size of 954 participants was required 
for a 90% chance of detecting a decrease in the proportion of patients with the 
primary outcome from 40 to 30% at a 2-sided significance level of 5%. The sample 
size was increased to 1150 to account for day-by-day cluster randomization, 
assuming an intraclass correlation coefficient of 0.10 and an average daily enrolment 
of 3 participants. 




Intention-to-treat analysis was used for statistical purposes. Our protocol also 
specified a per-protocol analysis and a contamination (a switch to the other device) 
adjusted intention-to-treat analysis. However, we decided before unblinding not to 
perform these analyses because a switch to the other device occurred for safety 
reasons at the discretion of the provider and was likely to be associated with poorer 
outcomes.  
Categorical data were recorded as frequency and percentage. Continuous data were 
recorded as median and IQR. The statistical analysis included both unadjusted and 
adjusted analyses. Outcome values were compared between the arms by the Chi 
Square test or Fisher’s exact test (unadjusted analysis). Generalized mixed-effect 
models were estimated to measure the effect of the treatment on outcome, adjusting 
for clusters (random effect) and unbalanced participant characteristics (adjusted 
analysis). Effect sizes were reported as relative risk with 95% confidence intervals.  
Data was rarely missing; hence the main analysis was based on complete cases. Post-
hoc sensitivity analysis was also used on the primary outcome measure (with missing 
data counted as failures in LMA arm and as successes in FM arm).  
All tests were 2-sided and P <0.05 again was considered significant. Data were 
analysed using R software, version 3.5 (R Foundation for Statistical Computing, 
Vienna, Austria).153 
  





5 Ethical considerations 
5.1 Emergency research and consent processes 
Neonatal resuscitation is carried out world-wide, but neonatal deaths mainly occur in 
low-resource settings due to improper birth care or neonatal resuscitation. Therefore, 
it is ethically relevant to conduct these studies in hospitals in low-resource settings. 
The NeoSupra Trial was run at Uganda’s largest national referral hospital which has 
a high number of deliveries. This made it possible to recruit the necessary number of 
participants within a reasonable time frame, which is also ethically relevant so that 
research funding is not wasted. Emergency research with critically unwell neonates, 
as in the NeoSupra Trial, is vital to understand how these neonates can benefit from 
evidence-based healthcare.155  
Ethical guidance requires that consent is sought from legal representatives on behalf 
of the neonates.156 Ethical frameworks has been established to ensure an effective 
system for review of research under research ethics committees that were 
independent of government and sponsors.157 This is to avoid suffering, show respect 
for cultural differences, and to prevent exploitation of the vulnerable. However, 
implementations of informed consent guidelines can also create barriers for getting 
potentially life-saving treatments in time.158,159  
The decision to participate in research extends beyond individual consent and further 
research should assess how medical care offers affects the decision to participate in 
trials.160 In the NeoSupra trial, a small travel compensation was given to all parents 
for follow-up visits, but no free medical care was offered.  
Collecting informed consent in neonates needing PPV before starting treatment was 
impossible as it would delay the intervention and diminish the neonate’s chance of 
survival. Furthermore, parents will usually be highly distressed in a critical care 
situation, and many will struggle to make an informed decision about research in the 
limited time available.161,162 We searched the literature regarding consents in 
emergency research, which was followed by extensive discussions with clinical 
experts on the Mulago Hospital Research and Ethics Committee (MHREC).158,161-170 




We agreed on a 2-tiered consent procedure. The procedure combined a prior brief 
oral consent with deferred consent - a possibility in potentially life-threatening 
situation suggested by existing guidelines and used in similar trials.156,171 Written and 
oral information was given to all parents on maternal admission from dedicated RAs, 
unless the mother was distressed or in second stage labour. A senior investigator was 
available at any time to discuss further questions concerning the trial. Deferred 
consent was obtained post-hoc from those mothers whose neonates were eligible for 
continuing participation.  
5.2 External monitoring, the NeoSupra Trial 
In the NeoSupra Trial article III, an independent data monitoring committee (IDMC) 
operated according to DAMOCLES procedures.172 In January 2019, a pre-planned 
interim analysis was carried out, allowing the trial to continue, which was conducted 
in accordance with the principles of the Declaration of Helsinki.156 
5.3 Management of stillbirths, the NeoSupra Trial 
To avoid misclassification and inclusion of fresh stillborn (born with no HR and 
breathing efforts), all neonates received at least 10 min ventilation. However, 
macerated neonates graded 0-1 (‘parboiled’ reddened skin or skin slippage and 
peeling) received only 1 min ventilation for ethical reasons.173 To clarify when 
neonatal resuscitation efforts should otherwise be terminated, we turned to the 
ILCOR international consensus on neonatal resuscitation, 2015, the Ugandan Clinical 
Guidelines, 2016, and HBB 2nd edition, and created a local resuscitation flow-chart 
approved by the hospital management.17,18,20,62,174 The flowchart was put on the wall 
of all 3 resuscitation tables during the entire recruitment process (Annex II). Health 
personnel were recommended to seek advice from doctor if there was no perceptible 
HR after 10 min or no spontaneous breathing after 20 min, even if the HR was 
adequate. A doctor would then take the decision to terminate the resuscitation. If no 
doctor was available, the health personnel were instructed to terminate the 
resuscitation themselves, following the time-limits of the flowchart.  
  





5.4 Safety and harms, the NeoSupra Trial  
Before the start of the NeoSupra Trial, standard operational procedures for the 
detection and reporting of AEs and serious adverse events (SAEs) were implemented. 
Rehearsals and ‘dry runs’ strengthened compliance to the protocol. AEs were defined 
as medical events that occur among study participants (resuscitated neonates) with or 
without a causal relationship with the use of resuscitation devices in the trial. SAEs 
were defined as AEs that: a) looked life threatening or resulted into death, b) required 
hospitalization or prolongation of existing hospitalization, c) were persistent or 
resulted in significant incapacity, d) were a disability not due to birth asphyxia, e) 
were an important medical condition based on the investigator’s judgement and on 
the Ugandan Human Subjects Protection Guidelines.175 Resuscitations were 
continuously monitored by video, observed by RAs and trial doctors to detect AEs 
and SAEs. Noted AEs were managed by hospital physicians and were followed until 
resolution or until a stable clinical endpoint had been reached. When the trial 
investigator became aware that an SAE had occurred, either expected or unexpected, 
and with or without any relationship to the use of the supraglottic airway, the 
appropriate SAE reporting form was completed as soon as possible, and a copy was 
submitted to MHREC immediately or in <7 days. Any Suspected Unexpected Serious 
Adverse Reactions (SUSARs) with or without a plausible causal relationship with the 
use of the LMA were also reported to the MHREC. A copy of the same report was 
emailed immediately to the trial sponsor. The incidence of SAEs was compared 
between the two trial arms by the IDMC during the interim analysis.  
5.5 Approvals  
The observational manikin study, article I, was approved by the Sachs’ Children and 
Youth Hospital, Stockholm, Sweden. 
The prospective observational study in 3 phases, article II, had different consent 
processes. In phase one, written informed consent was obtained from all low-end 
users (midwives). In phase two, written informed consent was obtained from the 
parents on maternal admission before admission to the operating room, and from 
high-end users. A senior investigator was available on the wards to discuss any 




queries concerning the trial. Data was collected as a sub-study of the ‘Randomized 
Clinical Trial Assessing Laryngeal Mask Airway Versus Face-Mask Ventilation in 
Neonatal Resuscitation (LMA vs FMV)’ (ClinicalTrials. gov NCT02042118), 
approved by the Institutional Review Board (IRB) of Mulago National Referral 
Hospital, Uganda, the Uganda National Council of Science and Technology, the 
Director-General from the Ministry of Health, Uganda and the Regional Committee 
for Medical and Health Research Ethics in Norway, No 2013/2096. In phase three, 
written and oral information was given to all parents on maternal admission, and 
deferred consent was obtained post-hoc in cases needing resuscitation. These data 
were collected as a sub-study of the NeoSupra Trial (ClinicalTrials.gov 
NCT03133572) approved by the Institutional Review Board (IRB) of Mulago 
National Referral Hospital, Uganda, the Uganda National Council of Science and 
Technology, the Director-General from the Ministry of Health, Uganda and the 
Regional Committee for Medical and Health Research Ethics in Norway, No 
2017/989. 
  





6 Summary of results 
6.1 Article I 
The first study in this thesis explored the accuracy and speed of NeoTapLS that aims 
to assess a neonate’s HR, showing that a simulated HR or pulse on a manikin could 
be accurately and rapidly assessed using the NeoTapLS. Thirty participants used 
NeoTapLS to determine 20 randomly selected simulated HRs by auscultation or 
palpation, 1200 simulations in total. As a true value, we used simulated HRs and 
pulses generated on a Laerdal SimNewB manikin that could present rates in multiples 
of 10. The estimated rates were arranged into 3 categories: very low (<60), low (60–
99) or normal (100 or above) according to international guideines.17 The simulated 
HRs were categorised into very low (20–50), low (60–90) or normal (100–140).  
Auscultation 
Of 600 simulations, we found a high correlation between estimated and simulated 
HRs across all categories (Pearson´s correlation coefficients = 0.993). The majority 
(93.5%) of auscultations differed by 5 beats or less from the true value. Only 3% of 
the estimated rates of simulated HRs were placed in a different category compared to 
the true value (Table 6), none being misclassified in the very low range. The 
estimations of simulated HRs at 60 and 100 were more prone to misclassification of 
category since they were cut-offs for the 3 categories. Excluding the simulated HRs 
of 60 and 100, only one was misclassified. The mean difference between the 
estimated and simulated HR was small, and the mean acquisition time for the 
estimated HR was 14.9 s. 
Palpation 
Of 600 simulations, was found a high correlation between estimated and simulated 
HRs (pulses) across all categories (Pearson´s correlation coefficients = 0.986). The 
majority (86.3%) of palpations differed by 5 beats or less from the true value. Some 
of estimated rates (6.5%) of simulated HRs were placed in a different category 
compared to the true value (Table 6). If we excluded the simulated HRs of 60 and 




100, 9 were misclassified. The mean difference between the estimated and simulated 
HR was small, and the mean acquisition time for the estimated HR was 16.3 s. 
Table 6. Simulated heart rate and estimated heart rate by auscultation and 
palpation, divided by categories, according to International Neonatal Resuscitation 
Guidelines.  
  Simulated heart rate 








































6.2 Article II 
In article II, a study in 3 phases, we assessed rates and heart rates with the NeoTapLS 
app. Clinical HR assessment was very fast, but clinical assessment of neonates 
needing PPV by low-end users (midwives) was less accurate than for high-end user in 
neonates not needing PPV.  
Phase one  
In this simulation, 18 midwives made 180 recordings of a metronome rhythm using 
NeoTapLS. There was a mean difference of −6 bpm, with 95% agreement limits of 
−26 to 14 bpm. Recordings ranged from 21 to 131 bpm, and the metronome was set 
from 30 to 130 bpm. In total 77% differed by 10 or less from the true value and 95% 
differed by 20 or less. 
Phase two  
In this clinical study, one paediatric specialist assessed 69 HRs with NeoTapLS on 33 
neonates not needing PPV compared to pulse oximetry. A mean difference of 3 bpm, 
with 95% agreement limits of −14 to 19 bpm, was found. HR ranged from 132 to 214 
bpm with NeoTapLS, and from 126 to 205 bpm with pulse oximetry. In total 88% 





differed by 10 or less from the true value and 96% differed by 20 or less. The median 
acquisition time for the estimated HR was 5 s. The characteristics of the neonates in 
phase two and three are given in Table 7. 
Table 7. Characteristics of neonates in Article II, phase two and three. 
Characteristics Phase two Phase three 
Number of neonates 33 98 
Number of recordings 69 235 
Need for positive pressure 
ventilation (PPV) 
No Yes 
Apgar 1 min 9 (IQR 9-9) 3 (IQR 2-4) 
Apgar 5 min 9 (IQR 9-10) 5 (IQR 4-6) 
Median weight (g) 3000 (IQR 2700-3390) 3100 (IQR 2750-3400) 
Time heart rate assessments 
after birth (s) 
120-1800 
(median 300, IQR 180-
600) 
100-720a 




Eighteen midwives assessed 235 HRs with NeoTapLS on 98 neonates needing PPV 
compared to ECG. A mean difference of 3 bpm was found, with 95% agreement 
limits of −48 to 53 bpm. HR ranged from 46 to 294 bpm with NeoTapLS, and from 
46 to 229 bpm with ECG. In total 48% differed by 10 or less from the true value and 
73% differed by 20 or less. NeoTapLS showed very good sensitivity (0.87) and 
specificity (0.96) in detecting bradycardia (HR <100 bpm; Table 8). The median 
acquisition time for the estimated HR was 2.7 s. 
 
Table 8: Distribution in categories of correctly and incorrectly recorded heart rates 
among midwives assessing neonates needing positive pressure ventilation (PPV) 









<60 bpm 1 1 0 
60-99 bpm 2 22 8 
≥100 bpm 0 4 197 
Data expressed as number of evaluations in each category 
 




6.3 Article III 
In this trial, 8.6% (1439) of the 16 791 neonates eligible for participation needed PPV 
at birth. The inclusion criteria were fulfilled for 1163 neonates; average cluster size 
was 3 neonates per 24 h cluster. After 9 lost to follow-up, 1154 were included in the 
analysis (Figure 22). Switch to the other device occurred in 3.5% in the LMA arm 
and 10.9% in the FM arm, the most common reasons being absent/poor chest 
movement and absent/poor HR improvement (article III Supplemental Appendix 
Table S1). Baseline characteristics were balanced between arms except for sex 
(article III Table 1).  
The primary outcome occurred in 27.4% of neonates in the LMA arm and 24.4% in 
the FM arm (Table 9). Very early neonatal death occurred in 15.8% in the LMA arm 
and 14.4% in the FM arm. There was no evidence that any of the secondary outcome 
measures differed substantially between arms (Table 9). About 61% had meconium-
stained and/or foul-smelling amniotic fluid. Few AEs occurred overall and there was 
no significant difference between the arms (article III Table 3). LMA did not reduce 
early neonatal death or moderate-to-severe HIE compared with FM in asphyxiated 
neonates. LMA was safe in the hands of midwives. 
Neonates switched from LMA to FM were more likely to be admitted to the NICU 
for HIE compared to those first receiving FM and then LMA (article III Supplemental 
Appendix Table S1). 
 






Figure 22. Enrolment and randomization of the participants. Published with the kind 
permission of The New England Journal of Medicine.  
 




Table 9. Outcome measures. Published with the kind permission of The New England 
Journal of Medicine.  
 





6.4 Suction practices 
In a sub-study of the NeoSupra Trial that included 46 participants, we collected more 
detailed data using a respiratory function monitor and video-reviewing. Suction was 
performed on 52.2% of the participants in the LMA arm and 56.6% in the FM arm. 
The median suction duration was 30 and 29 s, respectively. Obstruction of the 
airways with poor chest movements, low tidal volumes and bradycardia were 
recorded in 17.4% of the LMA cases and 47.8% of the FM cases (unpublished data). 
Of the 46 participants, 10 (22%, 4 in the LMA arm and 6 in the FM arm) received 
deep oral and/or tracheal suctioning with a modified Laerdal Penguin (Figure 23), 
improving HR and expired tidal volumes in all the treated participants. It seemed that 
severe mucus plugs caused the airway obstruction, insertion of LMA not resolving 
the problem.  
 
Figure 23. Laerdal Penguin suction device adapted for endotracheal suctioning. 
Photo: N. Pejovic. 
  





This thesis reports the development and investigation of innovations and new 
strategies in supporting neonatal resuscitation in low-resource settings, in which most 
neonatal mortality and morbidity occur. The findings will be discussed in the 
following order:  
• Innovations and new strategies 
• Heart rate assessment at birth  
• Laryngeal mask airway as primary device in neonatal resuscitation 
• Task-shifting heart rate assessment and laryngeal mask airway use to 
midwives 
• ILCOR 2020 Consensus on Sciences with Treatment Recommendations  
• And what about suction? 
• Methodological considerations 
• Other biases 
• Trials and the effect of new tools  
• Emergency research  
• The impact of a pandemic on neonatal mortality 
7.1 Innovations and new strategies 
The SDG 3.2 aims for a neonatal mortality rate of ≤12 per 1000 live births in all 
countries of the world before 2030, but many countries are lagging behind. State-of-
the-art neonatal resuscitation saves lives and also needs to be implemented in low-
resource settings, having high neonatal death rates. Current guidelines do not provide 
an alternative way to accurately assess HR where Doppler, pulse oximetry or ECG is 
unavailable. FMV is a difficult skill that cannot solve all airway problems. LMA is 
recommended when FMV proves unsuccessful, or where there is a lack of skills or 
equipment to insert an ETT.  
In low-resource settings, midwives are still in charge of neonatal resuscitations; one 
cannot rely only on doctors being available to evaluate neonates and initiate or 





maintain PPV. New data reports that an Apgar score at 5 and 10 min provides 
prognostic information about neonatal survival among preterm neonates.176 It is 
important that these scorings are based on good clinical examination by midwives. In 
referral hospitals of these settings, a high number of neonates need resuscitation at 
birth. Health personnel responsible for neonatal resuscitation need to be trained to 
master evaluation of HR and airway access since they are on the front line of these 
healthcare systems.  
7.1.1 mHealth apps and HR assessment 
Innovations and new strategies are of great importance for improving neonatal health, 
as highlighted in recent reviews.55,89,92,107,108,177 However, many factors influence the 
care that midwives can provide to neonates in low-resource settings. Implementing 
proven techniques, training existing health personnel sufficiently and providing 
midwives with already existing equipment and a good working environment, are 
probably the most important factors to get into place to reach the SDG 3.2 by 2030.55  
A qualitative study in Uganda in 2012 described the urgent need for in-depth 
understanding of knowledge translation of evidence-based interventions in low-
resource settings.109 Access to resources, commitment and community involvement 
are important in successful translation of knowledge and techniques.  
Global scale-up of the HBS initiative has been rapid and numerous bottlenecks, gaps 
and barriers having been highlighted.69 The HBS programme has now been scaled-up 
for a decade, and at the same time mobile phone ownership and access to cellular 
networks have increased quickly in low-resource settings. One report has described a 
number of HBS digital health innovations and resources developed between 2010 and 
2020 to support education and training, data collection for monitoring and evaluation, 
clinical decision support, and quality improvement.178 The authors concluded that 
thoughtful integration of purpose-built digital health tools, innovations and resources 
can assist HBS practitioners to more effectively disseminate and implement neonatal 
care programs. None of these innovations had incorporated the NeoTapLS tapping 
technique for HR assessment. 




However, the Liveborn app (Laerdal Global Health, Stavanger, Norway, freely 
downloadable on Google-play and App-store) launched in 2019 is one of these new 
apps supporting HBB implementation that actually has a HR monitoring option. The 
Liveborn app is used for live observation of neonatal care the first minutes after birth, 
similar to the NeoTapAS app. A recent review states a need for consensus guidelines 
and innovative solutions in the documentation of neonatal resuscitation.179 
Using Bluetooth technology, the Liveborn app can stream HR from the dry-electrode 
ECG NeoBeat. Apart from this feature, the app has manual registration of breathing 
status of neonates, and provider interventions and post-observation case summary. It is 
part of the Laerdal Safer Births Bundle serving to support healthcare workers and 
health systems globally to deliver better quality of care at birth, with increased 
efficiency and accountability. The Liveborn app have now been used at 12 hospitals 
in 4 countries between April 2019 to March 2020, and about 18 000 births have been 
observed, including 500 neonates needing PPV, but data are not yet available.   
7.1.2 Hypothermia treatment  
The NICU in our setting had no resources for therapeutic hypothermia, but new 
innovations in this area are under investigation that may overcome the issue of power 
shortage and long transports in the future. Examples of this are ice-packs and phase 
changing materials. These low-cost devices are safe and effective alternatives for 
maintaining therapeutic hypothermia in low-resource settings with adequate 
monitoring, but their impact on neonatal mortality and HIE in low-resource settings 
have still to be evaluated after further investigation.180,181 One must also be aware that 
neonates with severe HIE are more often subject to hypothermia due to passive 
cooling (drop in body temperature postpartum) than healthy neonates. This passive 
cooling must be taken into account when designing future clinical trials for low‐ and 
middle‐resource settings.182 
7.1.3 Implementation of innovations and new strategies  
Implementation of innovations and new strategies lies beyond the scope of this thesis, 
but still is important to consider. For example, cardiorespiratory monitoring devices 





are promising, but to understand their impact on neonatal outcomes in low-resource 
settings, early adopters should share their experiences broadly for better 
understanding of any implementation barrier.183 
NeoTapLS and NeoTapAS were developed with few app alternatives available on the 
market at the time. However, time has shown that mHealth tools are under 
investigation for implementation in low-resource settings. The NeoSupra Trial gave 
our team a unique insight into the context in a busy referral hospital, in sub-Saharan 
Africa, where midwives work. Our observations on NeoTapLS, the NeoSupra Trial 
(articles I-III), and upcoming investigation of mHealth apps will bring more clarity to 
innovations and new strategies in neonatal resuscitation in low-resource settings.  
7.2 Heart rate assessment at birth  
Measurement of HR at birth is important not only in assessment of the neonate 
needing PPV but is essential to avoid misclassification. A debated area in low-
resource settings is ‘fresh stillborn’. Annually 2.6 million stillbirths are reported, half 
being after the onset of labour.46,184 In Nepal up to 46% of intrapartum stillbirths were 
potentially misclassified.185,186 I chaired a qualitative focus group discussion in 2018, 
involving 44 midwives working at the High-risk Labour Ward and Operating Theatre, 
Mulago National Referral Hospital, Uganda.187 The group found that midwives had 
neither the knowledge nor the equipment to measure HR with a stethoscope at birth 
before the start of the NeoSupra Trial. They only palpated the cord or the chest to 
decide whether a neonate was alive (unpublished data). This technique is unreliable 
since deeply compromised neonates may not present with a cord pulse even if the 
heart is still beating.81 This may mislead health personnel in believing that the 
neonate is dead, and thereby misclassify him/her as a stillbirth even though proper 
PPV might have saved the neonate.  
A HR of 100 is the cut-off for normal HR and guides the resuscitator to re-evaluate 
ventilation and a HR of <60 suggests one should start heart compression according to 
the ILCOR guidelines.17,18,20 Reference to a normal HR in the first min after birth not 
needing PPV was investigated in 2010.14 The data were obtained by pulse oximetry, a 
method that might underestimate the HR compared to ECG.188 The study indicated 




that many neonates not needing PPV meet the criteria for interventions. A systemic 
review in 2019 reported again that pulse oximetry and ECG were precise, but took a 
considered amount of time to apply to the neonates.189 Using dry-electrode ECG, it 
was reported that HRs of <100 bpm were uncommon in neonates not needing PPV, 
accounting for <5% of neonates at 30 s after birth.190 For half of the neonates, the HR 
was detected from 13 s after birth, and 75% from 22 s, showing dry-electrode ECG to 
be a quick method. This further highlights the fact that incorrect estimations of HR 
could lead to impropriate management, and that precise, fast and easy-to-use methods 
are needed.  
7.2.1 Rate assessments in simulations by NeoTapLS 
The manikin study (article I) gave fast and accurate assessment of a simulated HR 
using NeoTapLS by 30 participants of different background, the first study of its 
kind. The metronome study (article II phase one) reported accurate assessment of a 
metronome rhythm by midwives using NeoTapLS. Furthermore, midwives 
overestimated low rates and underestimated high rates, which could be explained by 
anticipating that in low rates it is easy to tap too early, and in high rates it is difficult 
to maintain the high speed. Prior to the metronome study, one simulation study also 
reported that HR could be accurately and rapidly assessed using NeoTapAS (the Ipad 
version) on a manikin.191 In 2019, a randomized simulation trial showed that 
NeoTapAS reduced the time to the first HR, initiation of heart compressions and 
administration of epinephrine compared with auscultation and mental computation.192 
Following this, the use of a porcine model showed that HR assessment with 
NeoTapAS had a similar accuracy compared with auscultation using a digital 
stethoscope, ECG or carotid blood flow during asphyxia, and a faster acquisition time 
compared with the 6 or 10 s method with a digital stethoscope, wherein HR is 
calculated by multiplying the number of heartbeats heard in 6 s by 10 or in 10 s by 
6.193  
Prior to these studies, auscultation and palpation had led to incorrect management. 
Four reviews have pointed to problems regarding the inaccuracy of existing 
methods.89,92,177,189 A randomized simulation showed that up to 28% of simulated 





HRs obtained by auscultation led to incorrect management;83 and another simulation 
study reported that HRs of <60 bpm were inaccurate, giving overestimates.84 A 
prospective, randomized controlled study showed that errors in initial HR 
determination occurred in 26–48% of cases; an error in HR assessment was defined 
as a HR that differed by at least 15 bpm from the actual HR set on the simulator.82  
Our simulation studies showed that very few estimations fall on the wrong side of the 
cut-off levels, i.e. 60 and 100 bpm, and made it unlikely that it would lead to 
differences in the management of the neonate during resuscitation.  
7.2.2 Heart rate assessments in clinical use by NeoTapLS 
The clinical observations (article II phase two and three) indicated variable accuracy 
and precision in estimating HRs with NeoTapLS in HR auscultation, especially for 
midwives. The midwives could quickly learn the tapping technique and had very 
short acquisition times. The previous observation that midwives overestimated low 
simulated rates and underestimated high simulated rates was not seen in the clinical 
study. Data on the clinically important group of HR <60 bpm were few and show 
divergent results. This problem needs further investigation. In clinical use, this effect 
may be problematic at low HR, but with high HR it has minor implications as it does 
not change clinical decision-making. A new observation in clinical use was that a few 
recordings by midwives in phase three seemed to be twice the actual HR. This is an 
important finding, from which it is speculated that some midwives, inexperienced in 
listening to heart sounds, tapped on both the first and second heart sounds, i.e. 
tapping twice for a single heartbeat. This poses an obvious risk for errors in HR 
assessments by auscultation, independently of the use of NeoTapLS.  
Acquisition times were possibly too short in phase three, median 2.7 s, due to a 
misunderstanding of the ‘tap at least 3 times for HR’ feature of the app. NeoTapLS 
users should be reminded to tap until they are sure that they are tapping the same pace 
as the HR heard when auscultating the heart or palpating the pulse, the algorithm of 
NeoTapLS displays the average rate of the last 3 taps. 




Novel technologies including tap-based applications can support HR assessment150, 
but their clinical effectiveness during neonatal resuscitation needs to be further 
investigated. No other studies were found on HR assessments during neonatal 
resuscitation with nondoctoral health personnel. 
Our clinical study reported very few HR estimations that fell on the wrong side of the 
cut-off levels, making it unlikely that it could lead to differences in the management 
of the neonate during resuscitation. The results also showed that NeoTapLS was 
much faster than pulse oximetry and ECG. The findings add valuable information on 
NeoTapLS feasibility in clinical use.  
Awareness of the first and second heart sounds is essential; clinical studies have 
shown that training is crucial, with repeated training of health personnel affecting the 
management of patients.194,195 It is likely that clinicians would have obtained better 
results due to prior experience in HR auscultation.  
If midwives are trained to use a stethoscope, with the assistance of NeoTapLS, 
evaluation of HR may be more appropriate at birth and during PPV. This may lead to 
a decrease in interruption of ventilation and may be an alternative to expensive 
medical equipment. NeoTapLS may also be used for foetal HR monitoring. The 
inconsistent capacity to provide advanced resuscitation by local health personnel in 
our setting limits generalisation of the findings to better resourced settings. Future 
studies, including clinical trials that compare smartphone-assisted HR estimations to 
pulse oximetry or ECG, should provide more data on the potential of NeoTapLS prior 
to clinical use. 
7.3 Laryngeal mask airway as a primary device in neonatal resuscitation  
Prior reports, including a Cochrane review, have indicated that the use of LMA in 
neonatal resuscitation results in shorter ventilation times and faster pick-up in HR 
compared to FM.114,131,196-198 These studies were conducted in populations of mildly 
asphyxiated neonates. Resuscitations in previous studies were invariably carried out 
by doctors using LMAs with an inflatable cuff.136,197,199,200  





Our hypothesis was that a cuffless LMA as the primary device reduces early neonatal 
mortality and morbidity, even when used by midwives. In our setting with a high 
proportion of deeply compromised neonates of which 8.6% needed PPV, a safe and 
efficient airway access from the start of PPV could be of significant importance, since 
very early neonatal deaths were common. Comparing these numbers with previous 
reports2,201 suggests that our setting involved a sicker population, reflecting the 
hospital demographics, with a large number of late referrals. The limited resources at 
the NICU- for example, no access to therapeutic hypothemia treatment – may have a 
negative impact on the survival of these deeply compromised neonates. 
We had a higher rate of failure in treatment of the FM arm and more cases of LMA 
rescue, consistent with previous trials (article III Supplemental Appendix Table 
S1).114,197,198 The skills of the midwives changed - possibly improved - before and 
during the trial as a result of prior HBB training and repeated on-the-job training. 
More health personnel were present during the trial, and we task-shifted HR 
assessment to the midwives by providing them with personal stethoscopes. It was 
obvious that FMV skills improved among the midwives during the trial. This may 
explain why our trial did not demonstrate superiority of the LMA over FM but will be 
further investigated in upcoming video-review sub-studies to the NeoSupra Trial. The 
trial was not designed to assess non-inferiority of LMA use compared to FM meaning 
testing if the intervention arm is not worse than the control arm. The findings support 
current ILCOR recommendations.202,203 
This trial had a large number of subjects and a rigorous methodology, including video 
documentation, strong adherence to arm allocation and minimal loss to follow-up. It 
has extended our knowledge about the use of LMA among severely compromised 
neonates in a low-resource setting. It followed the CONSORT guidelines and thus 
help to guide future protocol.142,204 The results indicate that LMA can be safely used 
by trained midwives as an alternative device in neonatal resuscitation. LMA did not 
reduce early neonatal death or moderate-to-severe HIE. 




7.4 Task-shifting heart rate assessment and laryngeal mask airway use to 
midwives 
In many places in the world, non-doctor health personnel are the first to assess a 
neonate. High-volume referral hospitals in low-resource settings have a high delivery 
rate and a low number of health personnel, making it a challenging environment in 
which to implement complicated interventions. Midwives in these settings need our 
full attention if we are to reach the SDG 3.2 goal. Relying on doctors to save neonates 
in need of advanced resuscitation is unrealistic; it requires a new system of on-call 
service of doctors 24/7, as in high-resource settings, although this is unlikely to be 
before 2030. In obstetrics, innovative training of a mid-level workforce has improved 
accessibility of emergency care, including major surgery such as caesarean section, in 
low-resource settings. Data shows that outcomes are equal to surgery intervention by 
doctors, and these mid-level providers had a very high retention rate, i.e. it is a cost-
effective implementation.205  
As discussed above, inaccurate HR assessment can result in inappropriate actions. 
Not auscultating the heart could even mislead health personnel to think that a neonate 
is stillborn when, in fact, it is alive. The HBB 2nd edition does not teach one how to 
assess HR, even if the training kit includes a plastic stethoscope. Most health 
personnel in low-resource settings do not have full knowledge and skills to properly 
measure and assess the HR accurately, and most lack a suitable stethoscope. In my 
qualitive study, midwives said that stethoscopes are at present used by doctors, but 
they wanted to learn to use them.187 Auscultation-focused training and awareness of 
the first and second heart sounds could potentially improve clinical HR assessments 
by midwives; they need to be part of HBB training and in the routine assessments 
done by midwives.  
When starting the NeoSupra Trial, no prior trial using LMA had involved 
unsupervised midwives. Video filming was used for safety when midwives for the 
first time used the LMA unsupervised; the results showed few AEs. Our data support 
a smooth transition to midwives using LMA, neither should the step to introduce it to 
midwives in low-resource settings be controversial. The NeoSupra Trial provided 





solid evidence that skills acquired from LMA insertion on the manikin translates into 
good clinical practice.  
PPV with FM leads to many interruptions, >30% of the total ventilation time in high-
resource settings.96 LMAs, once inserted, could result in fewer interruptions, which 
may be beneficial to the neonates. LMA ventilation can also be done with one hand, 
an advantage in low-resource settings where there are fewer health personnel.  
A cuffless LMA was used in the NeoSupra Trial to create an efficient seal with the 
gel cushion to the larynx. This cuffless LMA is easy to position, with the risk of 
tissue damage or dislodgement being low.131,206 This makes it an ideal device in 
settings were ETT is unavailable.49 The cuffless single-use LMA used in this trial is 
currently too expensive for large-scale implementation, and multiple use options with 
inflatable cuff might be more feasible, although with the risk of delaying PPV, and 
therefore needs further investigation.  
In a large randomized controlled trial (RCT) comparing LMA versus ETT in 
paediatric anaesthesia, the ETT arm had 5 times more AEs than the LMA arm.129 Our 
phase II trial on LMA versus FM showed no AEs and the NeoSupra Trial had few 
AEs (2 cases of blood from mouth in each study arm, and no cases of laryngospasm 
or vomiting, article III Table 3). Few AEs confirm previous results, from which it can 
be concluded that LMA is safe in the hands of midwives.114 However, in a recent 
manikin study, proficiency in the insertion of LMA equivalent to the ETT was not 
apparent.207 Further studies need to investigate if and when LMA can replace ETT, 
which would give further support to LMA as a device suited for settings where 
midwives are in charge of neonatal resuscitation. 
7.5 ILCOR 2020 Consensus on Sciences with Treatment Recommendations  
The ILCOR 2020 CoSTR has been published without changes to the 2015 
recommendations related to HR assessments and the use of LMA.202,203 The report 
identifies 7 studies related to HR, including 2 reviews, published after the ILCOR 
2015 CoSTR systematic review.85,177,189,208-211 According to the ILCOR, the 2015 
treatment recommendation was fully supported. The ILCOR suggests ECG is used to 




provide a rapid and accurate estimation of HR, although the recommendation is weak 
and based on very poor evidence. A critical review of the 2020 ILCOR CoSTR did 
not agree with the authors claiming these studies support the 2015 
recommendation.212 They stated that several of the studies quoted do not recommend 
the use of ECG alone. They also pointed at a recent review from Tanzania 
demonstrating signals from ECG dry electrodes obtained as late as a median of 102 s 
after birth.213 The problem of pulseless electrical activity, a phenomenon that occurs 
when cardiac output is zero while the ECG still displays an HR, has also been 
highlighted.150 The review argues that The American Heart Association 
recommendation is more appropriate in stating that: “Auscultation of the precordium 
remains the preferred physical examination method for the initial assessment of the 
HR. Pulse oximetry and ECG remain important adjuncts to provide continuous HR 
assessment in babies needing resuscitation”.214 
Of note, the ILCOR upholds the need for new HR monitors, such as digital 
stethoscopes, photoplethysmography, Doppler ultrasonography methods with 
auditory or visual displays, and new interfaces for ECG monitoring, including dry-
electrode technology. They suggest that future CoSTR systematic reviews ought to 
compare these technologies to the current “gold standard” of ECG monitoring. They 
do not mention tap-based smartphone apps, even if they are discussed in one of the 2 
included reviews and released since 2015.177 LMA for neonatal resuscitation was not 
reviewed in 2020, the recommendations remaining the same. 
How proper HR and PPV are to be assessed in low-resource settings where training 
and adequate equipment may be lacking is still to be defined by the ILCOR.  
7.6 And what about suction? 
Suction-practice in neonatal resuscitation has been debated for years. Before the 2nd 
edition of HBB was launched, our team collected data by video-recordings on 99 
neonatal resuscitation at the Mulago National Referral Hospital in 2016.145 Suction 
practice did not follow the HBB guidelines and was delaying the start of PPV in the 
delivery room (median start of PPV 163 s, IQR 141-202; unpublished data). HBB 2nd 
edition de-emphasized suction, and during the NeoSupra Trial training prior to the 





start of the trial, we put special emphasis on avoiding prolonged suction and the 
starting of ventilation within 60 s after birth. But in a subgroup of the NeoSupra Trial 
cohort in which we collected data with a respiratory function monitor, we found 
mucus plugs caused airway obstruction during neonatal resuscitation in 22% of the 
cases. These cases needed aggressive suction seldom seen in the high-resource setting 
were the principal investigators usually work. The neonates recovered quickly after 
removal of the plugs with deep suction using a modified Penguin Suction Device 
(Figure 23), which would not be the case in meconium aspiration syndrome. The 
literature on suction does not highlight this issue but focuses on routine clearing of 
the airways before the start of PPV, as in HBB.215-218 Insertion of LMA did not seem 
to solve this clinical problem. In this population of severely compromised neonates, 
mucus plugs can be more common than in high-resource settings where there is better 
obstetric care. Active suction systems are rarely available in low-resource settings, 
but midwives can learn a deep suctioning technique that does not require active 
suction systems.  
7.7 Methodological considerations 
7.7.1 Methodological issues in the simulation studies, NeoTapLS 
Design of simulation studies has its limitations. It is close to an ideal situation, a 
controlled environment with limited stress, no interfering sounds or movement of the 
neonate, but it does not reflect the challenging environment of emergency care of 
neonates. However, it is always best ethically to test a new method in simulations 
before moving to clinical studies.  
In the simulations in article I and article II, phase one, one may consider the 
following methodological issues: 
• Article I: we used a high-fidelity manikin with HRs and pulses, but did not 
apply breathing movements  
• Article I: the manikin could only show numbers in multiples of 10  
• Article I: we used 30 participants from different professions, the selection 
being done on site, depending on who had the time without any randomization  




• Article II phase one: a metronome does not reflect the sound of a heartbeat 
• Article II phase one: we had few recordings and limited the rates to 30–150 
bpm 
7.7.2 Methodological issues in the clinical studies, NeoTapLS 
The design of clinical studies has other limitations compared to simulations. The 
setting is appropriate, but it is difficult to control the environment. However, clinical 
testing is essential to evaluate the feasibility of a method.  
In the clinical studies in article II, phase two and three, one may consider the 
following methodological issues: 
• Users and neonates were different for practical reasons  
• Included midwives had limited experience of HR auscultation 
• Participants in both phases were not masked to the true value  
• The true value was different for practical reasons  
• Phase two had a limited number of measurements for practical reasons, which 
was when investigators were on site in Uganda  
• Phase three had a large number of assessments, but was uncontrolled and 
unsupervised; timing of ECG and HR assessment was up to the user  
• We had few measurements of HR of <100 bpm and especially <60 bpm 
7.7.3 Bias considerations in the observational studies, NeoTapLS 
Bias is a systematic error due to design or method used affecting the interpretation of 
results. The main types in observational studies are selection and information bias. 
Random errors should be distinguished from bias and are related to the population 
and their impact on the results.  
Selection bias occurs when the participants included differ from eligible participants, 
affecting any generalization of the results.  
In article I, we included participants with a wide range of clinical resuscitation skills, 
but who were unfamiliar with the app. We disregarded any prior experience in 
smartphone management. The selection was done on site, depending on who had time 





- all the people approached agreed to take part in the study. No prior information 
about the study had reached eligible participants, which limits the possibility of 
potential selection bias.  
In article II, phase one and three, we selected all midwives employed as RAs in the 
NeoSupra Trial, and unfamiliar with the app. They were skilled in neonatal 
resuscitation and trained according to HBB 2nd edition as part of the NeoSupra Trial. 
They had limited training in auscultation of HR in neonates. We disregarded any 
prior experience in smartphone management, and all agreed to take part in the study. 
These midwives worked clinically at the labour wards and were therefore 
representative of the group. Although, they had all been involved in prior research 
projects, and therefore they would probably have a higher level of training and 
experience than the rest of the midwives at the hospital. This could have led to better 
performance in the selected group than the general group of midwives in Uganda. 
However, also these midwives had limited experience in HR auscultation. We do not 
know the results on less experienced health personnel in rural areas. Their 
performance would probably have been inferior.  
In article II, phase two, we selected 2 paediatric specialists well familiar with the app. 
These physicians were not representative of a wider group of physicians or midwives 
at the setting and therefore a potential selection bias might have influenced the 
results. These doctors probably have better skills than other doctors at the trial site, 
which is a weakness of the study. Neonates not needing PPV were selected only 
when the 2 specialists were on site in the daytime, possibly introducing potential 
selection bias since more staff are already there overlooking the births, leading to less 
distressed neonates.  
In article II phase three, we collected data from videos, in which only the hands of 
the midwives were seen. There is a risk that not all 18 midwives were included in the 
data-collection, but since they were all on duty during the inclusion-period and 98 
resuscitations were included, the risk was negligible. There was also little risk that the 
midwives appearing in the videos differed in skills from the rest of the group.         




We included all neonates needing PPV with simultaneous data from NeoTapLS and 
ECG during the study period, day and night, minimizing potential selection bias.  
Information bias refers to systematic errors in measurements, also referred to as 
measurement bias.  
Article I had 20 fixed true values in multiples of 10 on the manikin given as HRs and 
pulses. The participants were unaware of the limitations of the rate of the manikin, 
and this was unlikely to have affected the results. Participants were briefly introduced 
to NeoTapLS before the start of the study. The simulations could have been closer to 
a real scenario if we had added breathing movements, but the setup was designed to 
prove a concept and can be regarded as the equivalent of an in-vitro study in 
pharmacological trials. We did not separate the participants in the analysis of the 
data. 
As in article I, article II phase one had fixed true values from a metronome, equal to 
all participants. The metronome had no limitations in its rate; the range was set to 30–
150 bpm, but the midwives were not given this information. Midwives involved were 
briefly introduced to NeoTapLS before the start of the study, in which design 
minimizes the risk of potential information bias.  
The participants were not blinded to the true value in article II, phase two and three, 
adding potential information bias. It was possible to keep on tapping until the number 
was close to that given by pulse oximetry and ECG. However, the algorithm of 
NeoTapLS displays the average rate of the last 3 taps. The very short acquisition 
times de-emphasizes this point. 
In article II phase two, we used pulse oximetry as the true value. Pulse oximetry can 
display too low a HR during the first min of life.188,209,210,219 However, pulse oximetry 
data was collected at 120 s or more after birth, supporting the reliability of the results. 
However, it may have introduced a potential information bias.  
In article II phase three, we used ECG as the true value. This technique is 
recommended as gold standard by international guidelines because it is fast and 





accurate, but technical issues, such as wet skin of the neonates, could also introduce 
potential information bias.  
NeoTapLS introduces a potential information bias because it is up to the assessor to 
decide the time and the number of tapping on the screen needed to estimate the HR. 
The midwives in article II phase three did not assess the HRs directly when the 
neonates arrived at the table, and therefore probably missed checking HRs <60 bpm.  
Random errors should be distinguished from bias and are related to the population 
and their impact on the results. This effect can be decreased by a bigger sample size. 
A prospective approach was used in our observational studies to limit errors since 
retrospective studies are more prone to random errors. We also made a large number 
of simulations with no missing values. 
The firm methods and the lack of missing values in the simulation studies made the 
results trustworthy. Simulations indicated that moving to clinical studies was 
appropriate. Since the clinical results were accurate, swift and significant for doctors, 
it indicated that the app was user-friendly for a skilled group. The results for 
midwives were less accurate. However, the fact that true value, users and neonates 
were different, and the control over numbers in the clinical phases was limited, make 
it hard to generalise from the results. The great number of neonates involved gave us 
an indication on the limitations of NeoTapLS, and what requires further investigation. 
7.7.4 Methodological issues in the clinical trial, the NeoSupra Trial 
Studies that assign participants randomly into intervention or control groups are the 
RCTs, which are the best design to prove causality, i.e. the relationship between 
cause and effect. The design only allows us to look at the difference between the 
groups in terms of outcomes; if the randomization is done properly, it provides an 
unbiased assessment of the effects and safety of an intervention. Nevertheless, this 
design does not eliminate all potential errors at every level of the trial. 
A Cochrane Collaboration assessment tool to identify potential biases in trials 
showed low risk of bias arising from the randomization process, deviation from 




intended intervention and selection of the reported results, and high risk of potential 
bias due to missing outcome data and measurements of outcomes.220 
In article III, the NeoSupra Trial, one may consider the following methodological 
issues: 
• The participants were cluster-randomized to treatment by 24 h periods, for 
practical reasons  
• It was a single-site trial in a high-volume referral hospital of severely 
asphyxiated neonates  
• We had additional health personnel on site for safety reasons  
• The midwives knew the allocation of the day; blinding was not possible  
• Some switches occurred between arms as part of the trial design 
• There was limited training in managing advanced resuscitation by local health 
personnel 
• Outcome assessment of HIE was made by Thompson score without advanced 
exams, such as aEEG or cranial ultrasound 
• Lack of appropriate foetal HR monitoring made the initial distinction between 
stillbirth and live birth difficult  
7.7.5 Bias considerations in the clinical trial, the NeoSupra Trial 
Three major categories of errors are often mentioned in clinical trials: bias, 
confounding factors and random errors.  
Selection bias is introduced if the assigning of participants is not appropriate leading 
to a difference at baseline between the populations in the study arms. This can be 
solved by a solid design in randomization and selection. In this trial, we used 
randomization by day, each day representing a cluster. The randomisation list was 
generated by an independent statistician before the start of the trial, using block sizes 
of 4 to 8, dated and concealed until the assigned study day. The number of clusters 
was very high (>400) and the cluster size was small (only 3 neonates per cluster on 
average). This randomization method and the emergency nature of neonatal 
resuscitation limit any potential selection bias.  





The participant characteristics of the NeoSupra Trial were a population of severely 
asphyxiated neonates. It may not represent the population of asphyxiated neonates at 
large, but rather as a subgroup of the ‘worst affected’. The staff was also larger than 
normal for safety reasons. It is therefore uncertain whether the results can be 
generalized. Results from multi-centre trials are more solid to prove generalizability. 
Study management or performance bias is introduced when the blinding, procedure 
and training are inappropriate. 
In this trial, midwives performing neonatal resuscitation where not blinded to the 
intervention arm. Allocation concealment was in place but was given to the whole 
team each morning at 8:00 am. This knowledge of allocation could potentially have 
affected their behaviour in the day. If so, it was not obvious which direction this 
potential bias would go. The LMA had been introduced to the study site in a previous 
trial,114 and was favoured by some midwives. Others may have felt uncomfortable 
with the new device and favoured FM. The hypothesis of this trial may also introduce 
a belief that the LMA is a life-saving device; this may have led to unnecessary 
switches from FM to LMA. International guidelines state that if PPV with FM is 
ineffective, or if intubation is not successful, LMA may be used as a rescue airway. 
Health personnel were trained and advised to follow international recommendations 
and continue with the device of the day for 3 min, which may have limited any 
potential bias. 
Switches between groups may have contributed to improved outcome. Intention-to-
treat analysis is a method for analysing results where all randomized participants are 
included in the statistical analysis according to the arm to which they were originally 
assigned. If an intervention is truly effective, an intention-to-treat analysis will 
provide an unbiased estimate of its effectiveness. Understanding the effect the 
intervention has on patients is critical for decision-making, both in individual patients 
and populations. Intention-to-treat analysis is therefore the most appropriate way of 
informing a health policy issue. A per protocol analysis would have potentially biased 
the results, since switch to the other device occurred for safety reasons and was likely 
to be associated with poorer outcomes.221,222 




Limited training in managing advanced resuscitation by local health personnel also 
introduced limitations to the trial. We could not fully understand why the neonates 
died, and the assessment of surviving neonates by Thompson score were up to the 
individual assessor without firm outcomes. This potential bias is negligible in RCTs 
because they are likely to appear equally in both arms. 
Detection bias can occur during outcome determination by both investigators and 
observers, and adds a systematic difference between the study arms, however 
blinding of outcome assessors could reduce this potential risk. NICU physicians 
assessing HIE outcomes and the statistician were blinded to the arm allocation, 
limiting the risk of potential detection bias. The Thompson score was not confirmed 
by findings from aEEG or neuroimaging and could have been underestimated or 
overestimated. This potential bias and lack of appropriate foetal HR monitoring does 
not matter so much in RCTs, since they are likely to appear equally in arms. We also 
limited this potential bias by dry-runs prior to the start of the trial to test the method.  
The NeoSupra Trial had a low risk of potential volunteer bias in that the participants 
may not be representative due to few being unenrolled and a minimal loss to follow-
up.  
Attrition bias is a systematic error caused by unequal loss of participants from the 
study arms. Participants might withdraw due to AEs or death. This risk was obvious 
because of our 2-tiered consent procedure, further discussed in the section on 
emergency research (section 7.10). Potential attrition bias did not affect this trial; 
there was minimal loss to follow-up, 3/566 in the LMA arm and 6/597 in the FM arm. 
Publication or reporting bias occurs when the dissemination of research findings is 
selected after inclusion of the data. To mitigate this selection, we published our 
outcomes at clinicaltrials.gov prior to starting the trial and published the study 
protocol before finishing the inclusions of participants.142 We published the results, 
including those which did not support our hypothesis.  
Potential confounding factors that cannot be held constant are, for example, the size 
of neonates and their sex. Randomization is supposed to control these factors by 





generating comparable groups. We had a larger number of males than females in the 
LMA group. Male gender tends to be associated with increased risk of prematurity, 
respiratory distress syndrome and intrauterine growth restriction, with poorer 
outcomes than female neonates.223-227 We therefore adjusted for sex in the analysis.  
Random errors can be caused by numerous things, such as imprecision or 
inconsistencies in equipment used for data collection. These were considered and 
minimized by a large sample size.142 High-definition video recordings of all 
resuscitations, scanning of CRFs, double-data entry and extensive data cleaning 
further limited the risk of random errors since we could review and correct errors 
from the video recordings. The Apgar score was subjectively assessed on site and not 
double-checked by video. The fact that the reliability of the Apgar score is questioned 
introduced potential random errors.72  
The NeoSupra Trial had a high number of participants, well balanced groups and 
essentially no missing outcome data. The NeoSupra Trial has low risk of potential 
bias arising from the randomization process - deviation from intended intervention, 
selection of the reported results, and low risk of potential bias due to missing 
outcome data and measurements of outcomes. 
7.8 Other biases 
In article II phase three and article III, we video-filmed all the resuscitations carried 
out by the midwives. They were aware of the filming and the cameras were visible at 
the resuscitation tables, although at 2 tables had been hidden behind a warmer. The 
Hawthorne effect is as a consequence of participants being aware of being studied, 
which may affect their behaviour, i.e. the participants might actively drive the results 
towards the wishes of the researcher, a social equivalent to the ‘placebo effect’. In our 
trial, we have not actively evaluated this effect, which may have introduced a 
potential bias.228 However, even if the Hawthorne effect is involved, our impression 
has been that the midwives soon forgot about the cameras. This could be an effect of 
the emergency of the intervention, giving no time to reflect on filming of the events.  




7.9 Trials and new tools effect  
Performing a trial impacts on the study site in numerous ways affecting both arms. In 
the NeoSupra Trial, the awareness of neonatal resuscitation was increased by the 
training, the supply of materials, an increased number of health personnel, any 
clinical feedback to the midwives, optimization of the cleaning routines, and the 
introduction of a local flow chart (Annex II). The effects are not fully understood and 
new concepts are needed to evaluate them.228 A brief historical overlook of outcome 
data from the Mulago National Referral Hospital indicated a decrease in mortality 
rates during the trial affecting both arms. The introduction of new tools may also 
favour them as study participants and health personnel may feel that they are better 
than the standard of care already in use. This may have affected both the evaluation 
of NeoTapLS and the introduction of the uncuffed LMA.  
7.10 Emergency research 
As previously described, we agreed on a 2-tiered consent procedure for the NeoSupra 
Trial, a prior brief oral consent, with deferred consent on Day 1 after birth.  Cases of 
very early neonatal deaths was a challenge to the RAs since approaching distressed 
caregivers for deferred consent could be stressful and ethically difficult to justify. The 
inclusion of these participants was of utmost importance to the trial as death as an 
outcome was one of our primary concerns in the trial; there was inherently a risk that 
families losing a neonate would more likely drop out of the trial. This risk may have 
been especially high if the neonate was treated with the new device, LMA, since 
parents may be suspicious of new treatment protocols. After discussions with the 
RAs, we held on to the prior oral consent and deferred consents, even though 
informed consent would have been better in those particular cases. The benefit of not 
distressing all mothers entering the labour ward with extensive information on 
neonates needing PPV made this procedure best fitted to the context. The approach 
was successful and only a few mothers declined to give deferred consent. 
The deep involvement of MHREC in the decisions on how to address the consent 
issue in our trial was essential for the trial. The procedure of consent in the   





NeoSupra Trial was well suited for this context, but ethical guidelines for emergency 
resuscitation research need to be improved. 
7.11 The impact of a pandemic on neonatal mortality  
The data collection of this thesis was finalized before the outbreak of the latest 
pandemic due to coronavirus disease 2019, Covid-19. Logistically, it would have 
been difficult for me to undertake any observational studies and the NeoSupra Trial 
in Uganda during a pandemic. However, this thesis has been written during the 
pandemic; it feels right to mention any impact a pandemic may have had on neonatal 
mortality. The pandemic has disrupted many of the efforts taken towards the Every 
Newborn Action Plan and the SDG 3.2.54,229,230 Until the end of 2019, advances in 
many areas of health continued, but the rate of progress was insufficient to meet most 
SDG 3.2 targets. Essential health services and lifesaving interventions are now being 
disrupted, which threatens to reverse decades of improvements in health outcomes. 
Increase in stillbirths and neonatal mortality have been reported.231-233 One study 
provided evidence of the indirect effect of lockdowns in reducing institutional 
childbirth, as well as increasing the stillbirth rate and neonatal mortality.231 Reasons 
might include reduced intrapartum care, lack of supplies, decreased number of staff 
and delay in transports.234  
The pandemic will almost certainly have a negative effect on the progress towards the 
Every Newborn Action Plan and SDG 3.2, and will reduce research opportunities in 
low-resource settings. This will also have a negative effect on the implementation of 
innovations and new strategies and may be especially negative for neonates in low-
resource settings.  
  





This thesis extends our knowledge on innovations and new strategies, smartphone- 
and laryngeal mask airway use in cases where neonates are in need of positive 
pressure ventilation. More specifically:  
• A smartphone app can accurately and rapidly assist in assessing a simulated 
heart rate and pulse on a manikin and a metronome rhythm  
• Smartphone-assisted heart rate assessment by doctors is accurate and rapid in 
neonates not needing positive pressure ventilation in a low-resource setting  
• Smartphone-assisted heart rate assessment by midwives was less accurate in 
neonates needing positive pressure ventilation in a low-resource setting  
• The use of a laryngeal mask airway did not reduce early neonatal death or 
moderate-to-severe hypoxic-ischemic encephalopathy in asphyxiated neonates 
compared to face mask use 
• Laryngeal mask airway use proved safe in the hands of midwives and can be 
an alternative device during neonatal resuscitation 





9 Implications and future perspectives 
9.1 Implications for policy 
Midwives are the workforce primarily involved in saving neonates in low-resource 
settings, in which the majority of neonatal deaths occur. There is no single bullet 
solving the issue of neonatal mortality; midwives need our full attention if we are to 
reach the SDG 3.2 goal. To lower neonatal mortality, health systems need to be 
enforced at several levels, and innovations and new strategies need to be 
implemented where found useful and cost-effective. According to current guidelines, 
heart rate should be determined by auscultation or electrocardiography, and laryngeal 
mask airways should be used as an alternative device if face-mask ventilation is 
unsuccessful or endotracheal intubation is unavailable. The articles of this thesis add 
data supporting that: 
• Heart rate assessment of neonates by auscultation with support from a 
smartphone is fast and accurate when carried out by doctors  
• Helping Babies Breathe and other resuscitation training programs need to 
include auscultation-focused training in the curricula   
• Task-shifting of airway access to midwives, including training with advanced 
manikins, the technique of laryngeal mask airway insertion, and video filming 
need to be considered, especially at the referral level in low-resource settings  
• Midwives use the laryngeal mask airways safely 
• Laryngeal mask airways can be used by midwives as a secondary device 
according to current guidelines  
• WHO should consider adding laryngeal mask airway to the list of priority 
medical devices for essential reproductive, maternal, neonatal and child health 
• A cost-analysis of laryngeal mask airway use is necessary, since both single-
use and reusable models remain expensive 
  




9.2 Implications for further research 
Based on our experience, we strongly advise any future studies or trials in the field of 
neonatal resuscitation to use:  
• Video-recording  
• Dry-electrode electrocardiography 
Our studies left some unanswered questions:  
• How can smartphone apps best be used in training, teaching and clinical 
practice, both in small and large health facilities in low-resource settings? 
Clinical trials comparing smartphone-assisted HR estimations to dry-electrode 
electrocardiography could provide more data before clinical use 
• Is task-shifting of heart rate assessment to non-doctoral health personnel 
feasible in low-resource settings? 
• Can midwives be adequately trained to take over the responsibility of 
advanced resuscitation in low-resource settings? 
• Can a new curriculum for high-volume referral hospitals in low-resource 
settings affect neonatal mortality and morbidity? 
• Can laryngeal mask airway use affect mortality and morbidity in populations 
with less sick neonates? More detailed assessment of the outcome using 
electrocardiography and neuroimaging combined with Thompson scoring can 
clarify the results  
• Can laryngeal mask airway use decrease the need for endotracheal intubation? 
• Are mucus plugs causing airway obstruction during neonatal resuscitation 
more common in low-resource settings, and does aggressive suction solve the 
airway problem?  
• How do consent procedures and medical care offerings affect the decision to 
participate in emergency medicine research? 
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room are time-consuming, intermittent and often inaccu-
rate (7,8). Electrocardiography (ECG) is fast and accurate,
but is typically unavailable in resource-limited settings (9).
Pulse oximetry displays both pulse and saturation. In
neonatal resuscitation, the most important parameter is
the pulse of the newborn infant. Using pulse oximetry to
assess an infant’s heart rate can identify, with high sensi-
tivity and specificity, those infants who require interven-
tions based on current recommendations, but the procedure
is slow and is also often unavailable in resource-limited
settings (10). In one simulation study, where study
participants assessed heart rates by registering the heart
rate tapped out by an examiner using his or her finger, the
estimated heart rates showed little accuracy, especially at
rates of <60 beats per minute (11). The need to develop
a rapid and accurate method for determining heart rate
during newborn resuscitation has been highlighted (12–14).
A systematic review, published in 2017, explored the
accuracy of seven new technologies for monitoring the heart
rates of newborn infants and compared them to current
reference standards (13). The authors suggested that pairing
digital stethoscopes with a smartphone might improve
global assessments of heart rate, including resource-limited
settings. However, they concluded that the seven new
technologies tested could not be recommended as suitable
for widespread clinical use at that stage (13).
The 2015 International Liaison Committee on Resusci-
tation (ILCOR) guidelines state that progress beyond the
initial steps of newborn care, namely position of the airway,
suction if needed, drying and stimulation, is determined by
the simultaneous assessment of two vital characteristics:
respiration and a heart rate of <100 beats per minute.
Furthermore, chest compressions should be initiated if the
heart rate is <60 beats per minute, after having ensured that
the patient has adequate ventilation. ILCOR suggest that an
ECG should be used to evaluate heart rates in newborn
infants who need resuscitation, but an ECG does not
replace the need for pulse oximetry to evaluate the newborn
infant’s oxygenation (15). Compared to the 2010 ILCOR
guidelines, the new guidelines place less emphasis on
auscultation (6,15). However, when ECG and pulse oxime-
try are not available, auscultation is still recommended. The
current ILCOR guidelines do not provide other alternative
heart rate monitoring methods. Given that a great majority
of neonatal deaths occur in resource-limited settings, there
is an urgent need for a reliable, inexpensive and readily
available tool to assess heart rates under these conditions.
NeoTapLifeSupport (NeoTapLS) is a new free-of-charge
smartphone application that is designed to evaluate neona-
tal heart rates and was developed by our own nonprofit
organisation (Tap4Life, Stockholm, Sweden). The develop-
ment of this application responded to the demand identified
in our previous study for a method to assess the heart rate of
newborn infants in a fast and accurate way in a resource-
limited setting where no other reliable monitoring equip-
ment was available (16).
The user listens to the heart beat, or feels the pulse, of the
newborn infant and then taps the pace of the heart rate at
least three times on the screen of the smartphone. The
NeoTapLS then displays the heart rate as a number on the
screen. The interface is designed to be visible and functional
even when the smartphone is placed in a latex glove for
protection, which is useful in healthcare service in resource-
limited settings. The heart rate is also colour-coded: red for
a heart rate of <60, yellow for a heart rate of 60–99 and
green for a heart rate of 100 or more. The NeoTapLS is
downloadable free of charge at Google Play.
The aim of this manikin study was to determine the
accuracy and speed when participants with a range of
professional and educational backgrounds assessed a sim-
ulated heart rate using the NeoTapLS.
METHODS
Study participants
This observational study was conducted in 2014 at the
Centre for Education in Paediatric Simulation at Sachs’
Children and Youth Hospital in Stockholm, Sweden. It
tested the NeoTapLS, a new free-of-charge android appli-
cation. To cover a wide range of clinical resuscitation skills,
we recruited participants who were unfamiliar with the
NeoTapLS and came from a variety of professional and
educational backgrounds. All the people we approached
agreed to take part in the study, and any prior experience in
smartphone management was disregarded. We included 30
participants: eight doctors, six nurses, three nurse assistants,
six nurse students, two medical students, three secretaries
and two web designers.
The simulated heart rate, auscultated over the pre-
cordium or palpated by the pulse, was simultaneously
tapped onto the smartphone screen. After three taps, a
colour-coded number indicating the heart rate was dis-
played (Fig. 1).
A neonatal patient simulator, the Laerdal SimNewB
manikin (Laerdal Medical, Stavanger, Norway), was used
for the tests. This manikin is capable of generating heart
tones as well as umbilical and brachial pulsations. Before
starting the simulation, 20 heart rates, within the range of
20–140, were chosen using a random number generator
(17). As the manikin could only present in multiples of tens,
the numbers from the random number generator were
rounded to the nearest ten. The 20 heart rates were
presented to the participants in two orders, one for
auscultation and one for palpation. Participants were not
informed that the manikin could only present numbers in
tens. The participants were blinded to the selected heart
rates.
All users were introduced to the NeoTapLS and the
Laerdal SimNewB, and they familiarised themselves with
the set-up for three to five minutes prior to the simulation.
They were instructed to determine the heart rate by
auscultation of the precordium or palpation of the brachial
pulse of the Laerdal SimNewB manikin and simultaneously
tap the same pace on the screen of a smartphone, with the
NeoTapLS app installed. The simulation began by
the researcher telling the participants to start. As soon as
2 ©2018 The Authors. Acta Pædiatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Pædiatrica
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the participants were sure of the heart rate, they said stop
and reported the number. The acquisition time, defined as
the time from start to stop, was noted for all scenarios. Each
of the 30 participants carried out 20 estimations for
auscultation and 20 for palpation of the brachial pulse of
the Laerdal SimNewB, resulting in a total of 1200 readings.
Auscultation of the precordium was performed using a 3M
Littman Classic II Infant Stethoscope (3M, Minnesota,
USA). In all scenarios, the Laerdal SimNewB manikin was
lying on an open resuscitation table, without respiratory
frequency (Fig. 2).
Sachs’ Children and Youth Hospital, Stockholm, Swe-
den, approved the study. Further ethical approval was not
considered necessary for this study as it focused on the
accuracy and speed of the method and not on comparing
performance between individual participants or groups of
participants, similar to a previously published manikin
study (18). The participants gave oral consent to participate
and could decline participation at any time during the
study.
Statistical analysis
The analyses were performed using Stata Statistical Soft-
ware version 14.0 (StataCorp LP, College Station, Texas,
USA). Numerical variables were summarised with means,
ranges and standard deviations, and categorical variables
were summarised using frequencies. To compare correla-
tions between numerical variables, Pearson correlation
coefficients (r) were estimated. Results were presented with
95% confidence intervals (CI). All the inferential analyses
were adjusted to take into account the clustered nature of
the data, as the data clustered within individuals. P values of
<0.05 were considered significant.
RESULTS
The estimated heart rates were arranged into three cate-
gories: very low (<60), low (60–99) or normal (≥100). The
simulated heart rates were categorised into very low (20–
50), low (60–90) or normal (100–140). The heart rate of the
manikin, which was equal to the true value, will henceforth
be called the simulated heart rate.
Auscultation
The correlation between the estimated and simulated heart
rates was high (r = 0.993). It was lower in the normal range
(r = 0.920) compared to the very low (r = 0.974) and low
range (r = 0.974). Overall, 93.5% of all auscultations
differed by five beats or less from the true value (Fig. 3).
In all, 18/600 (3.0%) estimations of simulated heart rate
by the 30 participants were placed in a category that was
different to the actual category of the simulated heart rate
Figure 1 (A, B, C) How the NeoTapLS is displayed on the smartphone screen. Tap to register the infant’s heart rate. (A) Heart rate at 32 seconds <100, prepare for
ventilation. (B) Heart rate at one minute <100, ventilate now! (C) Heart rate at one minute 45 seconds >100, newborn resuscitation is going well.
©2018 The Authors. Acta Pædiatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Pædiatrica 3
Myrnerts H€o€ok et al. Smartphone heart rate application
(Table 1). In the very low range, none were misclassified.
Misclassifications were more likely to happen in the
estimations of simulated heart rates at 60 and 100 as they
were cut-offs for the three categories. We found that 2/30
were misclassified at 60 and 1/30 differed by five beats or
less from the simulated heart rate 60. Furthermore, 15/90
were misclassified at 100 and 12/90 differed by five beats or
less from the simulated heart rate of 100. If the 120
simulated heart rates of 60 and 100 were excluded, because
just a difference of one beat could lead to the wrong
categorisation, only one of the 480 (0.2%) estimations was
misclassified.
The mean difference between the estimated and simu-
lated heart rate was 0.79 beats per minute (95% CI !0.11 to
1.68). There was a slight, but constant, overestimation, and
this occurred more frequently in the normal range than in
the lower ranges. In the very low range, it was 0.39 beats per
minute (95% CI !0.03 to 0.81); in the low range, it was 0.68
beats per minute (95% CI 0.07 to 1.28); and in the normal
range, it was 1.14 beats per minute (95% CI !0.73 to 3.02).
The prevalence of correct estimations increased in a similar
way from the normal range to the very low range
(p value < 0.001) (Fig. 4A).
The mean acquisition time for the estimated heart rate
was 14.9 seconds (95% CI 13.42 to 16.40), ranging from
two to 80 seconds. The mean acquisition time was longer in
the very low range at 17.8 seconds (95% CI 16.5 to 19.2),
compared to 13.1 seconds in the low range (95% CI 11.5 to
14.6) and 13.4 seconds in the normal range (95% CI 11.6 to
15.3) (p value < 0.001).
Palpation
The correlation between the estimated and the simulated
heart rate for palpitation was high (r = 0.986), as it was for
auscultation. The correlation was highest in the very low
range (r = 0.956) and lower in the low range (r = 0.906).
The normal range had the lowest correlation (r = 0.840).
Overall, 86.3% of all palpations differed by five beats or less
from true value (Fig. 3).
In all, 39/600 (6.5%) estimations of simulated heart rate
by the 30 participants were placed in a category that was
different to the actual category of the simulated heart rate
(Table 1). We found that 7/30 were misclassified at 60 and
6/30 differed by five beats or less from the simulated heart
rate of 60. Furthermore, 23/90 were misclassified at 100
and 18/90 differed by five beats or less from the simulated
heart rate of 100. If the 120 simulated heart rates of 60 and
100 were excluded, again because just a difference of one
beat could lead to the wrong categorisation, 9/480 (1.9%)
estimations were misclassified.
The mean difference between the estimated and simu-
lated heart rate was !0.02 beats per minute (95% CI !1.08
to 1.04). In the very low range, it was 0.68 beats per minute
(95% CI 0.20 to 1.16); in the low range, it was !0.29 beats
per minute (95% CI !1.61 to 1.03); and in the normal
range, it was !0.44 beats per minute (95% CI !2.21 to
1.36). The estimated heart rates were not significantly lower
or higher than the simulated heart rates (p value 0.94),
meaning that there was no consistent over- or underesti-
mation (Fig. 4B).
The mean acquisition time for the estimated heart rate
was slightly longer than for auscultation, at 16.3 seconds
(95% CI 14.7 to 17.9), and it ranged from 5 to 62 seconds.
The mean acquisition time was 18.7 seconds in the very low
range (95% CI 17.3 to 20.1), 14.6 seconds in the low range
(95% CI 12.9 to 16.2) and 15.1 seconds in the normal range
(95% CI: 13.1;17.1) (p value < 0.001).
Figure 2 A simulation in which a participant, who agreed to be photographed,
auscultated the precordium of the manikin and at the same time tapped the
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Figure 3 Deviation from simulated heart rate by auscultation and palpation.
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DISCUSSION
This study showed that assessment of a simulated heart rate
in a manikin using a newly developed application for
smartphones, the NeoTapLS, was fast and accurate. Over-
all, 93.5% of the assessments made by auscultations and
86.3% of the assessments made by palpations differed by
five beats or less from the heart rate simulated by the
manikin.
Prior to our study, auscultation and palpation had
repeatedly been shown to lead to incorrect management,
even in manikin studies. One study found that up to 28% of
simulated heart rates obtained by auscultation led to
incorrect management (7), while another reported that
heart rates below 60 beats per minute were inaccurate and
overestimated simulated heart rate (11). A third study stated
that errors in initial heart rate determination occurred in
26–48% of the time (19). A clinical study reported poor
agreement between the assessments of heart rate in new-
born infants when both auscultation and palpation were
used (20). In healthy newborn infants, brachial and femoral
pulses are not reliable for determining heart rates (19,20)
and umbilical pulsations must not be relied upon whether
they are low or absent (20). Two reviews have pointed out
problems with the inaccuracy of existing methods (13,14).
In contrast, our study showed that very few heart rate
estimations fell on the wrong side of the cut-off levels at 100
beats per minute (2.7% of auscultations and 5.0% of
palpations) and 60 beats per minute (0.3% of auscultations
and 1.5% of palpations). If simulated heart rates of 60 and
100 were excluded, because just a difference of one beat
could lead to the wrong categorisation, an even smaller
number would be misclassified (0.2% of auscultations and
1.9% of palpations).
As 93.5% of the NeoTapLS-assisted auscultations and
86.3% of the NeoTapLS-assisted palpations differed by five
beats or less from the true value, it is unlikely that the
results would lead to major differences in the management
of cardiopulmonary resuscitations. A heart rate of 100 is the
cut-off for the definition of normal heart rate and guides the
resuscitator to re-evaluate ventilation and <60 is the cut-off
for initiating heart compression, according to the ILCOR
guidelines. This means that incorrect estimations when the
heart rate is near these cut-off points could eventually lead
to wrong assumptions about the status of the newborn
infant. Our findings are encouraging and may prevent
incorrect management in the resuscitation of newborn
infants (15).
Time is an extremely important factor in neonatal
resuscitation. ECG monitoring in the delivery room can be
time-consuming (8) and may be difficult to apply due to the
infant’s wet skin. Pulse oximetry is also time-consuming, it
needs an extra pair of hands, and it is often unreliable in the
delivery room, because it is sensitive to the excessive motion
and low blood perfusion displayed by newborn infants. One
study showed that it took a median of 68 seconds to obtain a
heart rate by pulse oximetry (10). Another study showed
that the time interval from attaching the pulse oximetry unit
to the first heart rate value appearing on the monitor was 84
seconds (range 35–132 seconds) (21). In fact, neither ECG
nor a conventional pulse oximetry is fast enough to enable
delivery room staff to follow the international resuscitation
guidelines for newborn infants. In our study, simulated
heart rate assessment was possible within one minute, with
few exceptions, and in most of the assessments, it took <20
seconds. This means that, at least under simulation condi-
tions, it is possible to use the heart rate information to guide
the management of the infant.
Furthermore, both ECGs and pulse oximetry are expen-
sive and are rarely available in resource-limited settings.
With the number of mobile phone users in the world
expected to pass the five billion mark in 2019, wireless
technology is expanding even in the most remote parts of
the world (22). The widespread use of mobile phones
highlights a significant opportunity to have a global impact
on health behaviours (23). Low-cost smartphones are
readily available and used at the patient’s bedside by an
increasing number of health workers (23). Free-of-charge
mobile health tools, like NeoTapLS, can be available for all
health workers who have access to a smartphone. In
addition, the smartphone can easily be protected by a glove.
A manikin study is close to an ideal situation for assessing
heart rate, or, in fact, simulated heart rate. There is little
stress, no interfering sounds, no dirt and none of the
movement seen in a real newborn infant. This is a limitation
of any manikin study (7). However, a manikin study can be
used to prove a concept that can then be tested further in
Table 1 Estimated heart rate and simulated heart rate by auscultation and palpation, divided by categories, according to the 2015 ILCOR guidelines












Estimated heart rate <60 By auscultation 210 (100) 2 (1.7) 0 (0)
By palpation 209 (99.5) 8 (6.7) 0 (0)
Estimated heart rate 60–99 By auscultation 0 (0) 117 (97.5) 15 (5.6)
By palpation 1 (0.5) 111 (92.5) 29 (10.7)
Estimated heart rate 100 or higher By auscultation 0 (0) 1 (0.8) 255 (94.4)
By palpation 0 (0) 1 (0.8) 241 (89.3)
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clinical environments. The manikin we used, the Laerdal
SimNewB, could only present numbers in multiples of 10,
but as the participants were not aware of this, it should not
have affected the results. Furthermore, as the 30 partici-
pants were from a number of different professions, and the
results were accurate, swift and significant for the entire
group, the results indicate that the application is user-
friendly and that it is possible to learn the required method
with just a few minutes training.
The results from our study are encouraging and suggest
that healthcare staff could avoid erroneous and delayed
estimations of heart rate if they used theNeoTapLS in clinical
practice. Our results also indicate that auscultation, with a
stethoscope over the precordiumof the newborn, should be a
preferred method to palpation. In the absence of a stetho-
scope, palpation combined with NeoTapLS may be an
alternative method for accurately and quickly assessing the





























































Figure 4 (A, B) Boxplot and whiskers showing all estimated heart rate assessments with NeoTapLS versus simulated heart rate of the manikin (A) by auscultation and
(B) by palpation.
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monitoring equipment fails or in the absence of any other
equipment. The ILCOR guidelines advocate auscultation for
initial heart rate assessment andECGor pulse oximetry if the
baby needs neonatal resuscitation and/or continuous respi-
ratory support. The ILCOR does not provide recommenda-
tions for other alternative methods of evaluating heart rates,
when expensive medical devices are unavailable. Mobile
health tools such as the NeoTapLS could fill this gap.
CONCLUSION
Our study showed that heart rates were accurately and
rapidly assessed using the NeoTapLS on a manikin. The
operators can start the NeoTapLS at the time of birth, and it
keeps track of the time and reminds them to start ventila-
tion at 60 seconds. NeoTapLS makes it possible to evaluate
the heart rate with a minimum interruption of ventilation,
even when only one resuscitator is in attendance. A globally
accessible mobile health system offers a low-cost alternative
to expensive medical equipment. Future studies, including
clinical trials that compare smartphone-assisted heart rate
estimations to ECG or pulse oximetry, could provide more
data on the potential of NeoTapLS prior to clinical use.
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What is known about the subject?
 ► Heart rate is crucial in evaluating the status of neo-
nates during resuscitation.
 ► Previous simulation studies and an animal model 
have shown that a smartphone application, NeoTap, 
offers fast and accurate heart rate monitoring.
 ► Clinical data on heart rate monitoring of neonates 
with a smartphone app are not yet available.
What this study adds?
 ► A smartphone application can improve speed and 
accuracy during heart rate assessment of neonates 
by auscultation in clinical setting.
 ► NeoTap could be a low- cost alternative to expensive 
medical equipment in both low- resource and high- 
resource settings.
ABSTRACT
Background Heart rate (HR) assessment is crucial 
in neonatal resuscitation, but pulse oximetry (PO) and 
electrocardiography (ECG) are rarely accessible in low- 
resource to middle- resource settings. This study evaluated 
a free- of- charge smartphone application, NeoTap, which 
records HR with a screen- tapping method bypassing 
mental arithmetic calculations.
Methods This observational study was carried out during 
three time periods between May 2015 and January 2019 
in Uganda in three phases. In phase 1, a metronome rate 
(n=180) was recorded by low- end users (midwives) using 
NeoTap. In phase 2, HR (n=69) in breathing neonates was 
recorded by high- end users (paediatricians) using NeoTap 
versus PO. In phase 3, HR (n=235) in non- breathing 
neonates was recorded by low- end users using NeoTap 
versus ECG.
Results In high- end users the mean difference was 3 
beats per minute (bpm) higher with NeoTap versus PO 
(95% agreement limits −14 to 19 bpm), with acquisition 
time of 5 seconds. In low- end users, the mean difference 
was 6 bpm lower with NeoTap versus metronome (95% 
agreement limits −26 to 14 bpm) and 3 bpm higher with 
NeoTap versus ECG in non- breathing neonates (95% 
agreement limits −48 to 53 bpm), with acquisition time of 
2.7 seconds. The agreement between NeoTap and ECG was 
good in the HR categories of 60–99 bpm and ≥100 bpm; 
HR <60 bpm had few measurements (kappa index 0.71, 
95% CI 0.63 to 0.79).
Conclusion HR could be accurately and rapidly assessed 
using a smartphone application in breathing neonates 
in a low- resource setting. Clinical assessment by low- 
end users was less accurate with wider CI but still adds 
clinically important information in non- breathing neonates. 
The authors suggest low- end users may benefit from 
auscultation- focused training. More research is needed to 
evaluate its feasibility in clinical use.
INTRODUCTION
Neonatal deaths stand at 47% of all deaths in 
children <5 years of age, equal to 2.5 million 
neonates dying in 2017, with about 1 million 
dying on the first day.1 2 Intrapartum- related 
events (birth asphyxia) stand at around 
0.66 million deaths (uncertainty range of 
0.42–1.05 million).3 Moreover, 2.6 million 
stillbirths occur every year, 50% after the 
onset of labour.4 Successful resuscitation 
could prevent many early neonatal deaths and 
decrease the morbidity of neonates surviving 
asphyxia.5
Heart rate (HR) is one of the most important 
clinical parameters in evaluating the status of 
a neonate, to guide neonatal resuscitation 
and to predict early neonatal mortality and 
morbidity.6–8 International guidelines state 
that resuscitation efforts should be guided by 
checking respiration and HR.7 9 Pulse oxim-
etry (PO) is valuable in monitoring HR and 
measuring oxygen saturation,10 11 but HR is 
measured faster and more accurately through 
electrocardiography (ECG).7 9 Auscultation, 
recommended when PO and ECG are unavail-
able, is often inaccurate.12–16 Doppler is not 
recommended in current international guide-
lines.7 9 Resource- limited settings rarely have 
PO, ECG or Doppler.17 In 2017, a systematic 
review investigated the accuracy of seven new 
technologies for monitoring HRs of neonates 
and concluded that none could be recom-
mended as suitable for widespread clinical use 
at this stage.18 The need to develop a low- cost, 
rapid and accurate alternative method for 
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Figure 1 Tap to record the neonate’s heart rate by the NeoTap application. Heart rate <100 bpm (yellow) at 37 s: prepare for 
ventilation. Heart rate <60 bpm (red) at 2 min and 11 s: start chest compressions? Heart rate ≥100 bpm (green) at 3 min and 
37 s: neonatal resuscitation is going well. bpm, beats per minute.
monitoring HR during neonatal resuscitation has been 
highlighted.18 19
NeoTap (NeoTap Life Support- NeoTapLS) is a free- of- 
charge smartphone app for HR recording (Google Play 
and App Store), developed by a non- profit organisation 
(Tap4Life, Stockholm, Sweden).20 21 It uses a screen- 
tapping method; the user auscultates the heart sounds 
and taps the beat on the screen a minimum of three 
times, and the app generates a number, bypassing mental 
arithmetic (figure 1). No probes are needed, and the 
interface is functional even when protected inside a latex 
glove. The app can also be used to estimate cord pulsa-
tions and fetal HR; an instructional video on ‘How to 
use NeoTapLS’ is available in online supplementary file 
2 and the full version is available on YouTube. A signif-
icant proportion of health personnel in low- resource 
settings have their own smartphone, a number that is 
increasing.22 NeoTap has shown promising results from 
three simulation studies and an animal model.23–26
The aim of our study was to evaluate NeoTap by deter-
mining the speed and accuracy at which users could 
assess a rhythm by a metronome (low- end users, midwives 
well familiar with neonatal resuscitation but with no prior 
experience of the tapping method), HR in breathing 
neonates (high- end users, paediatricians well familiar 
with the tapping method), and HR in neonates in need 
of positive pressure ventilation (PPV), equal to neonates 
with insufficient or no breathing at birth (low- end users). 
The hypothesis was that NeoTap is as fast or faster than 




This prospective observational study was carried out 
during three time periods between May 2015 and January 
2019. It is a substudy of the ‘Randomized Clinical Trial 
Assessing Laryngeal Mask Airway Versus Face- Mask Venti-
lation in Neonatal Resuscitation (LMA vs FMV)’ ( Clini-
calTrials. gov NCT02042118) and the ‘Neonatal Resusci-
tation with Supraglottic Airway Trial (NeoSupra)’ ( Clin-
icalTrials. gov NCT03133572), conducted at the Depart-
ment of Obstetrics and Gynaecology, Mulago National 
Referral Hospital, Uganda, which has around 25 000 
deliveries per year.
Data collection
The study had three phases to evaluate NeoTap by testing 
low- end users’ ability to tap a metronome rhythm and 
high- end and low- end users’ ability to tap a correct HR 
in clinical practice, as well as assess the swiftness of the 
method in clinical use. Low- end users in the first and third 
phases were research midwives and exposed on a daily 
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Figure 2 Low- end user using NeoTap to record heart rate 
(heart rate shown 147) and dry- electrode electrocardiography 
(heart rate shown 138). Picture used with written permission 
from the parents.
basis to neonatal resuscitation and trained according to 
Helping Babies Breathe, as part of the NeoSupra trial.27 
High- end users were two paediatric specialists. The users 
simultaneously tapped the pace of the rhythm of the 
metronome, or the HR they auscultated over the heart 
of the neonate, on the smartphone screen with the 
NeoTap app running. NeoTap is designed to display the 
average rate of the last three taps, meaning a number was 
displayed after a minimum of three taps (figure 2). The 
metronome was used as the true value in phase 1, HR by 
PO (PalmSAT 2500, Nonin Medical, Plymouth, USA) as 
the true value in phase 2 (no other monitoring equip-
ment was available at the time), and HR by ECG as the 
true value in phase 3. A convenience sample was chosen 
for each phase due to practical reasons and the explora-
tory nature of the study.
Phase 1: metronome rate by NeoTap (low-end users, a simulation)
In phase 1 we assessed the ability of low- end users to 
correctly record an audible metronome rhythm. Ten 
rates were randomly selected using a number generator 
set over the range of 20–150 beats per minute (bpm),28 
and the rates (masked to the participants) were presented 
by the metronome for approximately 20 s. Low- end users 
recorded the rate with the NeoTap, after first being intro-
duced to the app for 3–5 min, and wrote down the rate 
obtained on separate papers. The midwives included in 
the study were chosen irrespective of prior experience 
of smartphones. Informed consent was obtained from all 
participants.
Phase 2: HR by NeoTap versus PO (high-end users, healthy 
neonates)
In phase 2, we assessed the swiftness and ability of two 
high- end users to accurately record HR using NeoTap 
compared with PO in neonates not in need of PPV. PO 
was placed on the neonate on arrival on the resuscitation 
table by one high- end user and HR was assessed using 
NeoTap by the second high- end user as soon as HR was 
displayed by PO. Directly after HR was assessed using 
NeoTap, the second high- end user checked the HR on 
the PO (not masked to the participants) and noted both 
HRs on a paper. Acquisition time of NeoTap was noted 
(defined in seconds from start to end of tapping). Data 
were collected on- site when high- end users were avail-
able, and it was at this stage when it was unfeasible to 
involve low- end users since few were available. The first 
four paired HRs per neonate were collected. Informed 
consent was obtained from the parents on maternal 
admission and from the high- end users.
Phase 3: HR by NeoTap versus ECG (low-end users, neonates in 
need of PPV)
In phase 3, we assessed the swiftness and ability of low- end 
users to accurately record HR using NeoTap compared 
with ECG in neonates in need of PPV. ECG was placed 
on the neonate once feasible and HR was assessed using 
NeoTap when HR was displayed by ECG and compared 
with HR obtained by ECG at the same time (not masked 
to the participants). Low- end users were already intro-
duced to NeoTap in phase 1 and did not receive addi-
tional training prior to phase 3. The acquisition time of 
NeoTap was noted as in phase 2. No high- end users were 
available at the study site, and it was therefore not possible 
to include them. All resuscitations were video- recorded 
using an HD 1080P Black Box AI- IP018 camera (Shen-
zhen Aishine Electronics, China). The first 49 HR data 
were supervised by the researchers and collected on- site 
by traditional ECG (Philips Intellivue X2, Amsterdam, 
The Netherlands), and the rest were unsupervised and 
collected from video review with dry- electrode ECG 
(NeoBeat, Laerdal Global Health, Stavanger, Norway). 
All paired HRs (HR by NeoTap at the same time as HR by 
ECG) until end of resuscitation were collected; no upper 
limit was set for numbers of assessments per neonate 
(figure 2). All neonates lacking simultaneous data (only 
one device, poor signal acquisition or poor camera angle) 
were excluded (n=270). Data on Apgar and weight were 
double- entered using Android devices running the Open 
Data Kit V.2.0 tool suite.29 Written and oral information 
was given to all parents on maternal admission, and 
deferred consent was obtained post- hoc in cases needing 
resuscitation.27
Patient and public involvement
It was not appropriate to involve patients or the public 
in the design, or conduct, or reporting or dissemination 
plans for the study.
Data analysis
The agreement in phase 1 was assessed using a Bland- 
Altman plot (including Pearson’s correlation coefficient 
between HR difference and HR values). The agreement 
in phase 2 and 3 was assessed using a Bland- Altman plot 
for repeated measures (including repeated measure 
correlation between HR difference and HR values), and 
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Figure 3 Agreement between the metronome rhythm and 
the rate low- end users recorded using NeoTap: a simulation. 
Metronome rhythm is shown on the x- axis and the difference 
from recordings done by NeoTap on the y- axis (Bland- Altman 
plot) (data set in online supplementary file). bpm, beats per 
minute.
Table 1 Characteristics of neonates in phase 2 and 3 of 
the study







In need of PPV No Yes
Apgar 1 min 9 (IQR 9–9) 3 (IQR 2–4)
Apgar 5 min 9 (IQR 9–10) 5 (IQR 4–6)










*Exact data on time for measurements not possible to obtain 
through the method used in phase 3.
HR, heart rate; PPV, positive pressure ventilation.
Figure 4 Agreement between NeoTap and pulse oximetry 
among high- end users recording heart rate in healthy 
breathing neonates. Pulse oximetry recording is shown on 
the x- axis and the difference between the readings on the 
y- axis (Bland- Altman plot) (data set in online supplementary 
file). bpm, beats per minute.
in phase 3 using repeated measures version of kappa 
index on the following HR categories: <60, 60–99 and 
≥100 bpm. The sensitivity and specificity of NeoTap in 
detecting bradycardia (HR <100 bpm) were also calcu-
lated. Acquisition times in phase 2 and 3 were summa-
rised with median and IQR for descriptive purposes. 
Statistical analysis was performed using R V.3.5 (R Foun-
dation for Statistical Computing, Vienna, Austria).30
RESULTS
During the three phases we had no issues with the reli-
ability of the app. The app is designed to use very low 
resources from the phone and is continuously updated. 
It never crashed and froze and no battery problems 
occurred. The quality of the videos in phase 3 was excel-
lent, with only a few exclusions due to non- visible HR on 
NeoTap or ECG.
Phase 1: metronome rate by NeoTap (low-end users, a 
simulation)
One hundred and eighty recordings were assessed by 18 
low- end users. There was a mean difference of −6 bpm 
with NeoTap versus metronome, with 95% agreement 
limits of −26 to 14 bpm (Bland- Altman plot) (figure 3). 
The difference was inversely correlated with the metro-
nome rhythm (r=−0.50, p<0.0001), moving from an over-
estimation to an underestimation. NeoTap recordings 
ranged from 21 to 131 bpm, and the metronome was set 
at a range of 30–130 bpm. In total 77% differed by 10 or 
less from the true value and 95% differed by 20 or less.
Phase 2: HR by NeoTap versus PO (high-end users, healthy 
neonates)
Sixty- nine HR recordings were assessed on 33 neonates 
as soon as HR by PO was available, which was at 120 s or 
more after birth (table 1). There was a mean difference 
of 3 bpm with NeoTap versus PO, with 95% agreement 
limits of −14 to 19 bpm (Bland- Altman plot) (figure 4). 
The difference was inversely correlated with HR (r=−0.43, 
p=0.009); it decreased, not towards a zero difference, but 
towards a negative difference. HR ranged from 132 to 214 
bpm with NeoTap, and from 126 to 205 bpm with PO. 
The median acquisition time for the estimated HR was 5 s 
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Figure 5 Agreement between NeoTap and ECG among 
low- end users recording heart rate in non- breathing neonates 
during neonatal resuscitation. ECG recordings are shown on 
the x- axis and the difference between the readings on the 
y- axis (Bland- Altman plot) (data set in online supplementary 
file). bpm, beats per minute; ECG, electrocardiography.
Table 2 Distribution in categories of correctly and 
incorrectly recorded heart rates among midwives assessing 
neonates in need of positive pressure ventilation compared 
with electrocardiography, phase 3
NeoTap Electrocardiography
<60 bpm 60–99 bpm ≥100 bpm
<60 bpm 1 1 0
60–99 bpm 2 22 8
≥100 bpm 0 4 197
Data expressed as number of evaluations in each category.
bpm, beats per minute.
(IQR 5–5), ranging from 3 to 15 s. In total, 88% differed 
by 10 or less from the true value and 96% differed by 20 
or less.
Phase 3: HR by NeoTap versus ECG (low-end users, neonates 
in need of PPV)
Two hundred and thirty- five HR recordings were assessed 
by approximately 18 low- end users on 98 neonates 
(table 1). There was a mean difference of 3 bpm with 
NeoTap versus ECG, with 95% agreement limits of −48 
to 53 bpm, a difference that did not correlate with HR 
(r=−0.06, p=0.51) (Bland- Altman plot) (figure 5). HR 
ranged from 46 to 294 bpm with NeoTap, and from 46 to 
229 bpm with ECG. The median acquisition time for the 
estimated HR was 2.7 s (IQR 1.7–4.7), ranging from 0.8 to 
13.9 s. When HR was evaluated using the categories <60, 
60–99 and ≥100 bpm (table 2), the agreement between 
NeoTap and ECG was good (kappa index 0.71, 95% CI 
0.63 to 0.79). The <60 bpm category included only three 
recordings, with NeoTap differing +3, –12 and −25 from 
ECG. The 60–99 bpm category included 27 recordings 
differing by a median of 7 (IQR 5–14) from the true 
value, and the >100 bpm category included 205 record-
ings differing by a median of 12 (IQR 5–24) from the 
true value. In total, 48% differed 10 or less from the true 
value and 73% differed by 20 or less. Overall, NeoTap 
showed very good sensitivity (0.87) and specificity (0.96) 
in detecting bradycardia (HR <100 bpm).
The complete data set for all three phases is available 
in online supplementary file.
DISCUSSION
This study presents new data on the feasibility of using a 
smartphone app for swift and accurate HR assessments 
in neonates, both those in need and not in need of PPV. 
NeoTap showed variable accuracy and precision in esti-
mating rates and HRs, especially in low- end users in 
HR auscultation. Low- end users could quickly learn the 
tapping technique and both high- end and low- end users 
were quick in estimating HRs.
In low- resource settings, neonatal resuscitation is 
mainly carried out by health personnel with limited 
experience in both airway management and ausculta-
tion. Reliable monitoring equipment is rarely available.17 
HR assessment is inaccurate due to imprecise ausculta-
tion and palpation or errors in mental arithmetic calcula-
tion.12–16 31 Auscultation is a three- step procedure: first is 
auscultating the heart, second is understanding what you 
hear (first and second heart sounds) and third is trans-
lating it by calculation to provide a number. A recent 
clinical study showed that HR auscultation by clinicians 
compared with PO and ECG was quick and reasonably 
accurate in neonates not in need of PPV. Still, studies 
during neonatal resuscitation with less experienced 
health personnel are lacking.32 Although imprecise, 
international guidelines recommend HR determination 
by physical examination if no PO and/or ECG are avail-
able.7 9
NeoTap over- rides the need for mental arithmetic 
calculations. In 2018, two simulation studies reported 
that HR could be accurately and rapidly assessed using 
NeoTap on a manikin.23 24 In 2019, another simulation 
study showed that NeoTap reduced the time to the first 
HR and the time to initiate heart compressions and to 
administer epinephrine compared with auscultation and 
mental computation.25 A porcine model showed that HR 
assessment with NeoTap had similar accuracy compared 
with auscultation with a digital stethoscope, ECG or 
carotid blood flow during asphyxia and faster acquisition 
time compared with the 6 s or 10 s method with a digital 
stethoscope.26 However, data on the clinically important 
group of HR <60 bpm are few and show contradictory 
results in the studies above as well as in the present study. 
A recent review on HR assessment stated that novel tech-
nologies including tap- based applications can support 






jpo: first published as 10.1136/bm




6 Myrnerts Höök S, et al. BMJ Paediatrics Open 2020;4:e000688. doi:10.1136/bmjpo-2020-000688
Open access
HR assessment, but that their clinical efficacy during 
neonatal resuscitation has yet to be investigated.33
The accuracy in this study was highest among low- end 
users recording a metronome rhythm and in high- end 
users recording HR compared with PO in neonates not in 
need of PPV. In phase 1 there was an inverse correlation 
between the bpm presented and the difference—partic-
ipants overestimate low beats and underestimate high 
beats. We think this is because in low rates it is easy to tap 
too early and be too eager to tap the screen even when no 
sounds are presented, and in high rates it is hard to keep 
the high speed if you are not used to the tapping technic. 
In clinical use, this effect may be problematic in low HRs, 
but in high HRs it has minor clinical implications. Low- 
end users demonstrated the same mean difference in 
phase 3 as high- end users in phase 2, but with wider 95% 
agreement limits. Some recordings seemed to be twice 
the actual value. Health personnel, inexperienced in 
listening to hearts, may tap on both the first and second 
heart sounds, that is, tapping twice for each heart beat, 
a potential risk for errors in HR calculation even when 
auscultating without support from NeoTap. A qualitative 
study in our setting revealed that midwives did not assess 
HR by auscultation before the start of this study. Instead 
they palpated the cord or the chest.34 The midwives, 
however, accurately assessed the metronome rhythm. 
Auscultation- focused training and awareness of the first 
and second heart sounds could potentially improve clin-
ical HR assessment with the tapping method. Clinical 
studies have shown that training is crucial and repeated 
training of health personnel affects the management of 
patients.35 36 It is likely that clinicians would have obtained 
better results due to prior experience in HR auscultation, 
and a training module for HR auscultation in resuscita-
tion simulators could probably improve auscultation 
skills and performance of low- end users. Phase 3 shows 
few disagreements and narrow IQR ranges, and approx-
imately three- fourths of HRs differed 20 or less from the 
true value in the 60–99 bpm and ≥100 bpm categories, 
pointing at a high probability of adhering to guidelines.
There is need for a low- cost, rapid and accurate alterna-
tive method for monitoring HR during neonatal resusci-
tation in low- resource to middle- resource settings. Rapid 
and accurate decision- making is crucial in neonatal 
resuscitation and PO is too slow to fulfil international 
resuscitation guidelines.7 9 37 ECG is fast and accurate but 
may be difficult to apply on the wet torso of the neonate, 
leading to delayed application.38 39 NeoTap or other apps 
for HR assessment are potentially faster than PO and 
ECG, offering an alternative way to fulfil international 
guidelines.24 25 However, the reported acquisition times 
in phase 3 were possibly due to a misunderstanding of 
the ‘tap at least three times for HR’ feature of the app. 
Users should be reminded to tap until they feel confident 
of tapping the same pace as the HR they hear, still a swift 
method potentially leading to higher accuracy.
There are limitations to this study. Low- end users were 
skilled in neonatal resuscitation and were trained in 
Helping Babies Breathe shortly before the study started. 
The participants were part of an ongoing trial providing 
a better environment for auscultation. Less experienced 
healthcare providers in rural areas may produce inferior 
results. The gold standard is different for each of the 
three phases due to practical reasons, for example lack of 
ECG at the study site during phase 2. PO has high sensi-
tivity and specificity but may display a too low HR during 
the first minutes of life.40 PO in this study was used in 
neonates not in need of PPV at 120 s or more after birth, 
supporting the reliability of the PO data, and since 
NeoTap showed slightly higher HRs it points at NeoTap 
being accurate. The participants in phase 2 and 3 were 
not masked to the true value, introducing a potential 
bias, but the algorithm of NeoTap displays the average 
rate of the last three taps. This, combined with the very 
short acquisition times in both phases, de- emphasises this 
point. We had different users in the respective phases 
for practical reasons, making it harder to generalise the 
results. Most of the HR assessments in phase 3 were unsu-
pervised, meaning timing of placement of ECG and first 
HR assessment was up to the user. Also, in phase 3, we 
could not identify the users since only the hands were 
caught on the videos; therefore, the number of users 
in this phase is an approximation. Lastly, we had few 
measurements of HR <100 bpm and especially <60 bpm, 
limiting the possibility of evaluating the importance of 
the results in clinical practice.
CONCLUSION
NeoTap provides a low- cost technology well adapted to 
the context of low- resource settings. It can be used in 
an inexpensive smartphone for swift and accurate HR 
registration. Clinical assessment by low- end users was less 
accurate and the authors suggest they may benefit from 
auscultation- focused training. Further studies are needed 
to demonstrate whether smartphone apps are useful in 
clinical practice.
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